0001171843-18-003863.txt : 20180511 0001171843-18-003863.hdr.sgml : 20180511 20180511160105 ACCESSION NUMBER: 0001171843-18-003863 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 39 CONFORMED PERIOD OF REPORT: 20180331 FILED AS OF DATE: 20180511 DATE AS OF CHANGE: 20180511 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Capstone Therapeutics Corp. CENTRAL INDEX KEY: 0000887151 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 860585310 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-21214 FILM NUMBER: 18826789 BUSINESS ADDRESS: STREET 1: 1275 WEST WASHINGTON STREET STREET 2: SUITE 101 CITY: TEMPE STATE: AZ ZIP: 85281 BUSINESS PHONE: 6022865520 MAIL ADDRESS: STREET 1: 1275 WEST WASHINGTON STREET STREET 2: SUITE 101 CITY: TEMPE STATE: AZ ZIP: 85281 FORMER COMPANY: FORMER CONFORMED NAME: ORTHOLOGIC CORP DATE OF NAME CHANGE: 19940211 10-Q 1 f10q_051118.htm FORM 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 10-Q

(Mark One)

[ X ]

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended

March 31, 2018

[ ]

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from

Commission File Number: 0-21214

CAPSTONE THERAPEUTICS CORP.

(Exact name of registrant as specified in its charter)

Delaware	86-0585310
(State or other jurisdiction of incorporation or organization)	(IRS Employer Identification No.)

1275 W. Washington Street, Suite 104, Tempe, Arizona	85281
(Address of principal executive offices)	(Zip Code)

(602) 286-5520

(Registrant's telephone number, including area code)

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
☒ Yes ☐ No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

☒ Yes ☐ No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☐ (Do not check if a smaller reporting company)	Smaller reporting company	☒
Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
☐ Yes ☒No

APPLICABLE ONLY TO CORPORATE ISSUERS:

Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date.

54,385,411 shares of common stock outstanding as of May 1, 2018

CAPSTONE THERAPEUTICS CORP.

INDEX

			Page No.

	Forward Looking Statements		4

Part I	Financial Information

	Item 1.	Financial Statements (Unaudited)

		Condensed Consolidated Balance Sheets as of March 31, 2018 and December 31, 2017	5

		Condensed Consolidated Statements of Operations for the three months ended March 31, 2018 and 2017	6

		Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2018 and 2017	7

		Notes to Condensed Consolidated Financial Statements	8

	Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	19

	Item 4.	Controls and Procedures	22


Part II		Other Information

	Item 1.	Legal Proceedings	22

	Item 6.	Exhibits	22

EXHIBIT 101

Forward Looking Statements

We may from time to time make written or oral forward-looking statements, including statements contained in our filings with the Securities and Exchange Commission and our reports to stockholders. The safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 protects companies from liability for their forward looking statements if they comply with the requirements of that Act. This Quarterly Report on Form 10-Q should be read in conjunction with our Annual Report on Form 10-K for the year ended December 31, 2017, and contains forward-looking statements made pursuant to that safe harbor. These forward-looking statements relate to future events or to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. In some cases, you can identify forward-looking statements by the use of words such as “may,” “could,” “expect,” “intend,” “plan,” “seek,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue,” or the negative of these terms or other comparable terminology. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond our control and which could materially affect actual results, levels of activity, performance or achievements. Factors that may cause actual results to differ materially from current expectations, which we describe in more detail in this section titled “Risks,” include, but are not limited to:

failure of the Company, or its joint venture, LipimetiX Development, Inc., to obtain additional funds to continue operations;
the impact of the terms or conditions of agreements associated with funds obtained to fund operations;
failure to obtain additional funds required to complete clinical trials and supporting research and production efforts necessary to obtain FDA or comparable foreign agencies approval for product candidates or secure development agreements with pharmaceutical manufacturers;
the impact of using a virtual operating model;
unfavorable results of product candidate development efforts;
unfavorable results of pre-clinical or clinical testing;
delays in obtaining, or failure to obtain FDA or comparable foreign agencies approvals;
increased regulation by the FDA or comparable foreign agencies;
the introduction of competitive products;
impairment of license, patent or other proprietary rights;
the impact of present and future joint venture, collaborative or partnering agreements or the lack thereof;
failure of the Company’s common stock to continue to be listed at the OTCQB stock market; and
failure to successfully implement our drug development strategy for AEM-28 and its analogs.

If one or more of these or other risks or uncertainties materialize, or if our underlying assumptions prove to be incorrect, actual results may vary significantly from what we projected. Any forward-looking statement you read in this Quarterly Report on Form 10-Q reflects our current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, business strategy and liquidity. We assume no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

PART I – Financial Information

Item 1. Financial Statements

CAPSTONE THERAPEUTICS CORP.

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands, except share and per share data)

	March 31,			December 31,
	2018			2017
	(Unaudited)
ASSETS
Current assets
Cash and cash equivalents	$	805		$	1,275
Other current assets		76			98
Total current assets		881			1,373

Patent license rights, net		157			196
Total assets	$	1,038		$	1,569

LIABILITIES AND EQUITY
Current liabilities
Accounts payable	$	203		$	197
Other accrued liabilities		3			2
Total current liabilities		206			199

Secured debt and accrued interest, net of unamortized issuance costs		2,296			2,249

Equity
Capstone Therapeutics Corp. Stockholders' Equity
Common Stock $.0005 par value; 150,000,000 shares authorized; 54,385,411 shares outstanding in 2018 and 2017		27			27
Additional paid-in capital		190,470			190,468
Accumulated deficit		(191,961	)		(191,374	)
Total Capstone Therapeutics Corp. stockholders' equity (deficit)		(1,464	)		(879	)
Noncontrolling interest		-			-
Total equity		(1,464	)		(879	)
Total liabilities and equity	$	1,038		$	1,569

See notes to unaudited condensed consolidated financial statements

CAPSTONE THERAPEUTICS Corp.

CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS

(in thousands, except per share data)

(Unaudited)

	Three months ended March 31,
	2018			2017
OPERATING EXPENSES
General and administrative	$	229		$	113
Research and development		301			267
Total operating expenses		530			380

Interest and other expenses, net		60			15
Loss from operations before taxes		590			395
Income tax benefit		(3	)		(8	)
Net Loss		587			387

Less: Net Loss attributable to the noncontrolling interest		-			-
Net Loss attributable to Capstone Therapeutics Corp. stockholders	$	587		$	387
Per Share Information:
Net loss, basic and diluted, attributable to Capstone Therapeutics Corp. stockholders	$	0.01		$	0.01
Basic and diluted shares outstanding		54,385			40,885

See notes to unaudited condensed consolidated financial statements

CAPSTONE THERAPEUTICS Corp.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands)

(Unaudited)

	Three months ended March 31,
	2018			2017

OPERATING ACTIVITIES
Net loss	$	(587	)	$	(387	)
Non cash items:
Amortization		39			44
Non-cash interest expense		59			-
Non-cash stock based interest expense		2			-
Change in other operating items:
Other current assets		10			44
Accounts payable		6			75
Other accrued liabilities		1			12
Cash flows used in operating activities		(470	)		(212	)
INVESTING ACTIVITIES
Cash flows provided by investing activities		-			-
FINANCING ACTIVITIES
Cash flows provided by financing activities		-			-
NET DECREASE IN CASH AND CASH EQUIVALENTS		(470	)		(212	)
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD		1,275			698
CASH AND CASH EQUIVALENTS, END OF PERIOD	$	805		$	486

See notes to unaudited condensed consolidated financial statements

CAPSTONE THERAPEUTICS CORP.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

March 31, 2018

Note A.

OVERVIEW OF BUSINESS

Description of the Business

Capstone Therapeutics Corp. (the “Company”, “we”, “our” or “us”) is a biotechnology company committed to developing a pipeline of novel peptides and other molecules aimed at helping patients with under-served medical conditions. Previously, we were focused on the development and commercialization of two product platforms: AZX100 and Chrysalin (TP508). In 2012, we terminated the license for Chrysalin (targeting orthopedic indications). In 2014, we terminated the license for AZX100 (targeting dermal scar reduction). Capstone no longer has any rights to or interest in Chrysalin or AZX100.

On August 3, 2012, we entered into a joint venture, LipimetiX Development, LLC, (now LipimetiX Development, Inc.), (the “JV”), to develop Apo E mimetic peptide molecule AEM-28 and its analogs. The JV has a development plan to pursue regulatory approval of AEM-28, or an analog, as treatment for Homozygous Familial Hypercholesterolemia, other hyperlipidemic indications, and acute coronary syndrome/atherosclerosis regression. The initial AEM-28 development plan extended through Phase 1a and 1b/2a clinical trials and was completed in the fourth quarter of 2014. The clinical trials had a safety primary endpoint and an efficacy endpoint targeting reduction of cholesterol and triglycerides.

In early 2014, the JV received allowance from regulatory authorities in Australia permitting the JV to proceed with the planned clinical trials. The Phase 1a clinical trial commenced in Australia in April 2014 and the Phase 1b/2a clinical trial commenced in Australia in June 2014. The clinical trials for AEM-28 were randomized, double-blinded, placebo-controlled studies to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of six escalating single doses (Phase 1a in healthy patients with elevated cholesterol) and multiple ascending doses of the three highest doses from Phase 1a (Phase 1b/2a in patients with hypercholesterolemia and healthy volunteers with elevated cholesterol and high Body Mass Index). The Phase 1a clinical trial consisted of 36 patients and the Phase 1b/2a consisted of 15 patients. Both clinical trials were completed in 2014 and the Medical Safety Committee, reviewing all safety-related aspects of the clinical trials, observed a generally acceptable safety profile. As first-in-man studies, the primary endpoint was safety; yet efficacy measurements analyzing pharmacodynamics yielded statistical significance in the pooled dataset favoring AEM-28 versus placebo in multiple lipid biomarker endpoints.

Concurrent with the clinical development activities of AEM-28, the JV has performed pre-clinical studies that have identified analogs of AEM-28, and new formulations, that have the potential of increased efficacy, higher human dose toleration and an extended composition of matter patent life (application filed with the U.S. Patent and Trademark Office in 2014).

The JV and the Company are exploring fundraising, partnering or licensing, to obtain additional funding to continue development activities and operations.

The JV and the Company do not have sufficient funding at this time to continue additional material development activities. The JV may conduct future clinical trials in Australia, the USA, and other regulatory jurisdictions if regulatory approvals, additional funding, and other conditions permit.

The Company, funding permitting, intends to continue limiting its internal operations to a virtual operating model while monitoring and participating in the management of JV’s development activities.

Description of Current Peptide Drug Candidates.

Apo E Mimetic Peptide Molecule – AEM-28 and its analogs

Apolipoprotein E is a 299 amino acid protein that plays an important role in lipoprotein metabolism. Apolipoprotein E (Apo E) is in a class of protein that occurs throughout the body. Apo E is essential for the normal metabolism of cholesterol and triglycerides. After a meal, the postprandial (or post-meal) lipid load is packaged in lipoproteins and secreted into the blood stream. Apo E targets cholesterol and triglyceride rich lipoproteins to specific receptors in the liver, decreasing the levels in the blood. Elevated plasma cholesterol and triglycerides are independent risk factors for atherosclerosis, the buildup of cholesterol rich lesions and plaques in the arteries. AEM-28 is a 28 amino acid mimetic of Apo E and AEM-28 analogs are also 28 amino acid mimetics of Apo E (with an aminohexanoic acid group and a phospholipid). Both contain a domain that anchors into a lipoprotein surface while also providing the Apo E receptor binding domain, which allows clearance through the heparan sulfate proteoglycan (HSPG) receptors (Syndecan-1) in the liver. AEM-28 and its analogs, as Apo E mimetics, have the potential to restore the ability of these atherogenic lipoproteins to be cleared from the plasma, completing the reverse cholesterol transport pathway, and thereby reducing cardiovascular risk. This is an important mechanism of action for AEM-28 and its analogs. Atherosclerosis is the major cause of cardiovascular disease, peripheral artery disease and cerebral artery disease, and can cause heart attack, loss of limbs and stroke. Defective lipid metabolism also plays an important role in the development of adult onset diabetes mellitus (Type 2 diabetes), and diabetics are particularly vulnerable to atherosclerosis, heart and peripheral artery diseases. Our joint venture has an Exclusive License Agreement with the University of Alabama at Birmingham Research Foundation for a broad domain of Apo E mimetic peptides, including AEM-28 and its analogs.

Company History

Prior to November 2003, we developed, manufactured and marketed proprietary, technologically advanced orthopedic products designed to promote the healing of musculoskeletal bone and tissue, with particular emphasis on fracture healing and spine repair. Our product lines, which included bone growth stimulation and fracture fixation devices, are referred to as our “Bone Device Business.” In November 2003, we sold our Bone Device Business.

In August 2004, we purchased substantially all of the assets and intellectual property of Chrysalis Biotechnology, Inc., including its exclusive worldwide license for Chrysalin, a peptide, for all medical indications. Subsequently, our efforts were focused on research and development of Chrysalin with the goal of commercializing our products in fresh fracture healing. (In March 2012, we returned all rights to the Chrysalin intellectual property and no longer have any interest in, or rights to, Chrysalin.)

In February 2006, we purchased certain assets and assumed certain liabilities of AzERx, Inc. Under the terms of the transaction, we acquired an exclusive license for the core intellectual property relating to AZX100, an anti-fibrotic peptide. In 2014, we terminated the License Agreement with AzTE (Licensor) for the core intellectual property relating to AZX100 and returned all interest in and rights to the AZX100 intellectual property to the Licensor.

On August 3, 2012, we entered into a joint venture (As described in Note B below) to develop Apo E mimetic peptide molecule AEM-28 and its analogs.

Our development activities represent a single operating segment as they shared the same product development path and utilized the same Company resources. As a result, we determined that it is appropriate to reflect our operations as one reportable segment.

OrthoLogic Corp. commenced doing business under the trade name of Capstone Therapeutics on October 1, 2008, and we formally changed our name from OrthoLogic Corp. to Capstone Therapeutics Corp. on May 21, 2010.

In these notes, references to “we”, “our”, “us”, the “Company”, “Capstone Therapeutics”, “Capstone”, and “OrthoLogic” refer to Capstone Therapeutics Corp. References to our joint venture or “JV”, refer to LipimetiX Development, Inc. (formerly LipimetiX Development, LLC).

Basis of presentation, Going Concern, and Management’s Plans. The accompanying financials statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business.

Management has determined that the Company will require additional capital above its current cash and working capital balances to further develop AEM-28 and its analogs or to continue operations. Accordingly, the Company has significantly reduced its development activities. The Company’s corporate strategy is to raise funds by possibly engaging in a strategic/merger transaction or conducting a private or public offering of debt or equity securities for capital. In August 2016, the Company’s joint venture raised net funds of $946,000 in a Series B-1 Preferred Stock and Warrant offering. As described in Note E below, the Company, on July 14, 2017, raised $3,440,000, with net proceeds of approximately $2,074,000, after paying off the Convertible Promissory Notes described in Note D below, and transaction costs of $287,000. As discussed in Note B below, in August 2017, the Company used $1,000,000 of the net proceeds to purchase 93,458 shares of LipimetiX Development, Inc.’s Series B-2 Preferred Stock. The additional funds has alleviated the substantial doubt about the entity’s ability to continue as a going concern; however, additional funds will be required for the joint venture to reach its development goals and for the Company to continue its planned operations.

In the opinion of management, the unaudited condensed interim financial statements include all adjustments necessary for the fair presentation of our financial position, results of operations, and cash flows, and all adjustments were of a normal recurring nature. The results of operations for the interim periods are not necessarily indicative of the results to be expected for the complete fiscal year. The financial statements include the consolidated results of Capstone Therapeutics Corp. and our approximately 60% owned subsidiary, LipimetiX Development, Inc. Intercompany transactions have been eliminated.

Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted pursuant to Securities and Exchange Commission rules and regulations, although we believe that the disclosures herein are adequate to make the information presented not misleading. These unaudited condensed financial statements should be read in conjunction with the financial statements and the notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2017. Information presented as of December 31, 2017 is derived from audited financial statements.

Use of estimates. The preparation of financial statements in accordance with accounting principles generally accepted in the United States of America requires that management make a number of assumptions and estimates that affect the reported amounts of assets, liabilities, and expenses in our financial statements and accompanying notes. Management bases its estimates on historical experience and various other assumptions believed to be reasonable. Although these estimates are based on management’s assumptions regarding current events and actions that may impact the Company in the future, actual results may differ from these estimates and assumptions.

Our significant estimates include income taxes, contingencies, accounting for stock-based compensation, and accounting for the Australian refundable research and development tax credit.

Legal and Other Contingencies

The Company is subject to legal proceedings and claims, as well as potential inquires and action by the Securities and Exchange Commission, that arise in the course of business. The Company records a liability when it is probable that a loss has been incurred and the amount is reasonably estimable. There is significant judgment required in both the probability determination and as to whether an exposure can be reasonably estimated. In the opinion of management, there was not at least a reasonable possibility the Company may have incurred a material loss with respect to loss contingencies. However, the outcome of legal proceedings and claims brought against the Company are subject to significant uncertainty.

Legal costs related to contingencies are expensed as incurred and were not material in either 2018 or 2017.

Joint Venture Accounting. The Company entered into a joint venture in which it has contributed $6,000,000, and the noncontrolling interests have contributed certain patent license rights. As discussed in Note B below, in August 2017, the Company purchased 93,458 shares of LipimetiX Development, Inc.’s Series B-2 Preferred Stock for $1,000,000. Neither the Company nor the noncontrolling interests have an obligation to contribute additional funds to the joint venture or to assume any joint venture liabilities or to provide a guarantee of either joint venture performance or any joint venture liability. The financial position and results of operations of the joint venture are presented on a consolidated basis with the financial position and results of operations of the Company. Intercompany transactions have been eliminated. Joint venture losses were recorded on the basis of common ownership equity interests until common ownership equity was reduced to $0. Subsequent joint venture losses were allocated to the Series A preferred ownership. Subsequent to March 31, 2013, all joint venture losses had been allocated to the Company. On August 25, 2016, the JV raised $1,012,000 ($946,000 net of issuance costs) in a Series B-1 Preferred Stock and Warrant offering and in 2016, $946,000 in losses were allocated to the Series B-1 Preferred Stock ownership interests. As of March 31, 2018, losses incurred by the JV exceeded the capital accounts of the JV. The Company has a revolving loan agreement with the joint venture and advanced the joint venture funds for operations in an amount of $1,600,000, with the net amount due December 31, 2016. As described in Note B below, the due date of the revolving loan has been extended to July 15, 2020, with early payment required upon certain additional funding of the joint venture by non-affiliated parties. Losses incurred by the joint venture in excess of the capital accounts of the joint venture will be allocated to the Company to the extent of net outstanding advances.

Cash and cash equivalents.

Cash and cash equivalents consist of highly liquid investments with an original maturity of three months or less.

Revenue Recognition

In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU 606”) No. 2014-09 “Revenue from Contracts from Customers”. Pursuant to ASC 606, revenue is recognized by the Company when a customer obtains control of promised goods or services. The amount of revenue that is recorded reflects the consideration that the Company expects to receive in exchange for those goods or services. The Company applies the following five-step model in order to determine this amount: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation.

Upfront License Fees: If a license to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from nonrefundable, upfront license fees based on the relative value prescribed to the license compared to the total value of the arrangement. The revenue is recognized when the license is transferred to the collaborator and the collaborator is able to use and benefit from the license. For licenses that are not distinct from other obligations identified in the arrangement, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time. If the combined performance obligation is satisfied over time, the Company applies an appropriate method of measuring progress for purposes of recognizing revenue from nonrefundable, upfront license fees. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.

Note B.

JOINT VENTURE FOR DEVELOPMENT OF APO E MIMETIC PEPTIDE MOLECULE AEM-28 AND ANALOGS

On August 3, 2012, we entered into a Contribution Agreement with LipimetiX, LLC to form a joint venture, LipimetiX Development, LLC (“JV”), to develop Apo E mimetic molecules, including AEM-28 and its analogs. In June 2015, the JV converted from a limited liability company to a corporation, LipimetiX Development, Inc. The Company contributed $6 million, which included $1 million for 600,000 voting common ownership units (now common stock), representing 60% ownership in the JV, and $5 million for 5,000,000 non-voting preferred ownership units (now Series A Preferred Stock), which have preferential distribution rights. On March 31, 2016, the Company converted 1,500,000 shares of its preferred stock into 120,000 shares of common stock, increasing its common stock ownership from 60% to 64%. On August 11, 2017, the remaining $3,500,000 (3,500,000 shares) of Series A preferred stock became convertible, at the Company’s option, into common stock, at the lower of the Series B Preferred Stock Conversion Price, as may be adjusted for certain events, or the price of the next LipimetiX Development, Inc. financing, exceeding $1,000,000 on independently set valuation and terms. On August 11, 2017, the Company purchased 93,458 shares of LipimetiX Development, Inc.’s Series B-2 Preferred Stock for $1,000,000 (LipimetiX Development, Inc. incurred $15,000 in transaction costs as part of the Series B-2 Preferred Stock issuance, which was been shown in our Annual Report on Form 10-K for the year ended December 31, 2017 filed with the Securities and Exchange Commission on February 28, 2018, as a reduction of Additional Paid in Capital on the Consolidated Statements of Changes in Equity and a cash flow provided by financing activities in the Consolidated Statements of Cash Flows at December 31, 2017). As discussed below, the JV Series B-1 and B-2 Preferred Stock issuances, because of the participating and conversion features of the preferred stock, effectively changes the Company’s ownership in the JV to 62.2%. With the Series B-1 and B-2 Preferred Stock on an as-converted basis, and the Company converting its Series A Preferred Stock to common stock, the Company’s ownership would change to 69.75%. The JV 2016 Equity Incentive Plan has 83,480 shares of the JV’s common stock available to grant, of which, at March 31, 2018, options to purchase JV common stock shares totaling 81,479 have been granted. All options were granted with an exercise price of $1.07, vest 50% on the date of grant and monthly thereafter in equal amounts over a twenty-four-month period and are exercisable for ten years from the date of grant. If all stock available to grant in the JV 2016 Equity Incentive Plan were granted and exercised, and the Series B-1 Preferred Stock Warrants were exercised, the Company’s fully diluted ownership (on an as-converted basis) would be approximately 65.11%. On October 27, 2017 the Board granted Mr. Holliman an option to purchase14,126 shares of the LipimetiX Development, Inc. Series B-2 Preferred Stock it currently owns, at an exercise price of $10.70 per share, subject to adjustment and other terms consistent with the Series B-2 Preferred Stock. The option is exercisable for a five-year period from the date of grant. If exercised, this option would reduce the Company’s fully diluted ownership (on an as-converted basis including assumed exercise of other options and warrants) to approximately 64.31%.

LipimetiX, LLC was formed by the principals of Benu BioPharma, Inc. (“Benu”) and UABRF to commercialize UABRF’s intellectual property related to Apo E mimetic molecules, including AEM-28 and analogs. Benu is currently composed of Dennis I. Goldberg, Ph.D. and Eric M. Morrel, Ph.D. LipimetiX, LLC contributed all intellectual property rights for Apo E mimetic molecules it owned and assigned its Exclusive License Agreement between The University of Alabama at Birmingham Research Foundation (“UABRF”) and LipimetiX, LLC, for the UABRF intellectual property related to Apo E mimetic molecules AEM-28 and its analogs to the JV, in return for 400,000 voting common ownership units (now common stock), representing a 40% ownership interest in the JV at formation, and $378,000 in cash (for certain initial patent-related costs and legal expenses).

On August 25, 2016, LipimetiX Development, Inc. closed a Series B-1 Preferred Stock offering, raising funds of $1,012,000 ($946,000 net of issuance costs of approximately $66,000). Individual accredited investors and management participated in the financing. This initial closing of the Series B-1 Preferred Stock offering resulted in the issuance of 94,537 shares of preferred stock, convertible to an equal number of the JV’s common stock at the election of the holders and warrants to purchase an additional 33,088 shares of JV preferred stock, at an exercise price of $10.70, with a ten-year term.

As disclosed above, on August 11, 2017, the Company purchased 93,458 shares of LipimetiX Development, Inc.’s Series B-2 Preferred Stock for $1,000,000.

Series B (B-1 and B-2) Preferred Stock is a participating preferred stock. As a participating preferred, the preferred stock will earn a 5% dividend, payable only upon the election by the JV or in liquidation. Prior to the JV common stock holders receiving distributions, the participating preferred stockholders will receive their earned dividends and payback of their original investment. Subsequently, the participating preferred will participate in future distributions on an equal “as-converted” share basis with common stock holders. The Series B Preferred Stock has “as-converted” voting rights and other terms standard to a security of this nature.

The Exclusive License Agreement assigned by LipimetiX, LLC to the JV on formation of the JV, as amended, calls for payment of patent filing, maintenance and other related patent fees, as well as a royalty of 3% on Net Sales of Licensed Products during the Term of the Agreement. The Agreement terminates upon the expiration of all Valid Patent Claims within the Licensed Patents, which are currently estimated to expire between 2019 and 2035. The Agreement, as amended, also calls for annual maintenance payments of $25,000, various milestone payments of $50,000 to $500,000 and minimum royalty payments of $500,000 to $1,000,000 per year commencing on January 1 of the first calendar year following the year in which the First Commercial Sale occurs. UABRF will also be paid 5% of Non-Royalty Income received.

Concurrent with entering into the Contribution Agreement and the First Amendment and Consent to Assignment of Exclusive License Agreement between LipimetiX, LLC, UABRF and the Company, the Company and LipimetiX, LLC entered into a Limited Liability Company Agreement for JV which established a Joint Development Committee (“JDC”) to manage JV development activities. Upon conversion by the JV from a limited liability company to a corporation, the parties entered into a Stockholders Agreement for the JV, and the JDC was replaced by a Board of Directors (JV Board). The JV Board is composed of three members appointed by the non-Company common stock ownership group, three members appointed by the Company and one member appointed by the Series B-1 Preferred Stockholders. Non-development JV decisions, including the issuance of new equity, incurrence of debt, entry into strategic transactions, licenses or development agreements, sales of assets and liquidation, and approval of annual budgets, will be decided by a majority vote of the common and Series B Preferred Stock (voting on an “as -converted” basis) stockholders.

The JV, on August 3, 2012, entered into a Management Agreement with Benu to manage JV development activities for a monthly fee of approximately $63,000 during the twenty-seven-month development period, and an Accounting Services Agreement with the Company to manage JV accounting and administrative functions. The services related to these agreements have been completed. New Management and Accounting Services Agreements were entered into effective June 1, 2016. The new monthly management fee is $80,000 and the new monthly accounting services fee was $10,000. However, no Management or Accounting Services fees are due or payable except to the extent funding is available, as unanimously approved by members of the JV Board of Directors and as reflected in the approved operating budget in effect at that time. In connection with the Series B-1 Preferred Stock issuance, Management Fees totaling $300,000, of which $250,000 was charged to expense in 2016 and $50,000 was charged to expense in the first quarter of 2017, and Accounting Fees totaling $60,000, charged to expense in 2016, were paid in 2016. In August 2017 the Accounting Services Agreement monthly fee was increased to $20,000 and will thereafter be accrued but not payable, until certain levels of joint venture funding are obtained from non-affiliated parties. At March 31, 2018, accounting fees of $160,000 were earned but unpaid. In August 2017, a Management Fee of $300,000 was approved by the joint venture’s Board of Directors with $150,000 paid and charged to expense in the third quarter of 2017 and $150,000 paid and expensed in the first quarter of 2018.

The joint venture formation was as follows ($000’s):

Patent license rights	$	1,045
Noncontrolling interests		(667	)
Cash paid at formation	$	378

Patent license rights were recorded at their estimated fair value and are being amortized on a straight-line basis over the key patent life of eighty months.

The financial position and results of operations of the joint venture are presented on a consolidated basis with the financial position and results of operations of the Company. Intercompany transactions have been eliminated. In the Company’s consolidated financial statements, joint venture losses were recorded on the basis of common ownership equity interests until common ownership equity was reduced to $0. Subsequent joint venture losses were being allocated to the Series A preferred ownership equity (100% Company). Subsequent to March 31, 2013, all joint venture losses had been allocated to the Company. On August 25, 2016 the JV raised $1,012,000, ($946,000 net of issuance costs) in a Series B-1 Preferred Stock and Warrant offering and in 2016, $946,000 of losses were allocated to the Series B-1 Preferred Stock ownership interests. As of March 31, 2018, losses incurred by the JV exceeded the capital accounts of the JV. The Company has a revolving loan agreement with the joint venture, with the loan due December 31, 2016. In August 2017, the due date of the revolving loan was extended to July 15, 2020, with early payment required upon certain additional funding of the joint venture by non-affiliated parties. Subsequent to June 30, 2017, interest due on the revolving loan will be accrued and payable only upon certain additional funding of the joint venture by non-affiliated parties. Until repayment, the outstanding revolving loan and interest balance is convertible, at the Company’s option, into Series B Preferred Stock at the Series B-1 conversion price. Losses incurred by the joint venture in excess of the capital accounts of the joint venture will be allocated to the Company to the extent of the unpaid loan and accrued interest balance. At March 31, 2018, the revolving loan agreement balance, including accrued interest subsequent to June 30, 2017 of $60,000, was $1,660,000.

The joint venture incurred net operating expenses, prior to the elimination of intercompany transactions, of $427,000 in 2018 and $10,078,000 for the period from August 3, 2012 (inception) to March 31, 2018, of which $427,000, and $8,466,000, respectively, have been recorded by the Company. The joint venture operating expenses are included in research and development expenses in the condensed consolidated statements of operations.

Neither the Company nor the noncontrolling interests have an obligation to contribute additional funds to the joint venture or to assume any joint venture liabilities or to provide a guarantee of either joint venture performance or any joint venture liability. Losses allocated to the common stock noncontrolling interests represent an additional potential loss for the Company as the common stock noncontrolling interests are not obligated to contribute assets to the joint venture and, depending on the ultimate outcome of the joint venture, the Company could potentially absorb all losses associated with the joint venture. From formation of the joint venture, August 3, 2012, through March 31, 2018, losses totaling $667,000 have been allocated to the common stock noncontrolling interests. If the joint venture or Company is unable to obtain additional funding, the ability of the joint venture to continue development of AEM-28 and its analogs would be impaired as would the joint venture’s ability to continue operations. If the joint venture does not continue as a going concern, at March 31, 2018 the Company would incur an additional loss of $667,000 for the joint venture losses allocated to the common stock noncontrolling interests.

Note C.

Australian Refundable Research & Development Credit

In March 2014, LipimetiX Development LLC, (Now LipimetiX Development, Inc. - see Note B above) formed a wholly-owned Australian subsidiary, Lipimetix Australia Pty Ltd, to conduct Phase 1a and Phase1b/2a clinical trials in Australia. Currently Australian tax regulations provide for a refundable research and development tax credit equal to either 43.5% or 45% (depending on the tax period) of qualified expenditures. Subsequent to the end of its Australian tax years, Lipimetix Australia Pty Ltd submits claims for a refundable research and development tax credit. At March 31, 2018 and December 31, 2017, expected refundable research and development tax credits of AUD$46,000 and AUD$42,000, respectively, are included in Other current assets in the Condensed Consolidated Balance Sheets. The expected refundable research and development tax credits for the three-month periods ended March 31, 2018 and 2017 were AUD$4,000 and AUD$11,000, respectively.

Note D.

CONVERTIBLE PROMISSORY NOTES

On December 11, 2015, we entered into a Securities Purchase Agreement with Biotechnology Value Fund affiliated entities Biotechnology Value Fund, L.P., Biotechnology Value Fund II, L.P., Biotechnology Value Trading Fund OS, L.P., Investment 10, LLC, and MSI BVF SPV,), which provided $1,000,000 in funding for our operations in the form of Convertible Promissory Notes (“Notes”). The Notes bear interest at 5% and were due April 30, 2017, with the due date subsequently extended to July 14, 2017. The Notes were secured by all intangible and tangible assets of the Company and convertible, either at the election of the Lenders or mandatory on certain future funding events, into either the Company’s Common or Preferred Stock. A portion of the funds were advanced to JV to initiate preclinical development activities. As described in Note E below, the Convertible Promissory Notes and accrued interest thereon of $79,000 were paid off on July 14, 2017. Prior to the July 14, 2017 transaction, the Biotechnology Value Fund affiliated entities owned approximately 19% of our outstanding common stock.

Note E.

SALE OF COMMON STOCK AND ISSUANCE OFSECURED debT

As described in our Current Report on Form 8-K filed with the Securities and Exchange Commission on July 17, 2017, on July 14, 2017, the Company entered into a Securities Purchase, Loan and Security Agreement (the “Agreement”) with BP Peptides, LLC (“Brookstone"). The net proceeds will be used to fund our operations, infuse new capital into our joint venture, LipimetiX Development, Inc. ("JV") (As described in Note B above, in August 2017, the Company used $1,000,000 of the net proceeds to purchase 93,458 shares of LipimetiX Development, Inc.’s Series B-2 Preferred Stock.), to continue its development activities, and pay off the Convertible Promissory Notes (as described in Note D above) totaling $1,000,000, plus $79,000 in accrued interest.

Pursuant to the Agreement, Brookstone funded an aggregate of $3,440,000, with net proceeds of approximately $2,074,000, after paying off the Convertible Promissory Notes and transaction costs, of which $1,012,500 was for the purchase of 13,500,000 newly issued shares of our Common Stock, and $2,427,500 was in the form of a secured loan, due October 15, 2020. On July 14, 2017 Brookstone also purchased 5,041,197 shares of the Company’s Common Stock directly from Biotechnology Value Fund affiliated entities, resulting in ownership of 18,541,197 shares of the Company’s Common Stock, representing approximately 34.1% of outstanding shares of the Company’s Common Stock at March 31, 2018. Transaction costs of $287,000 have been deferred and will be written off over the life of the secured loan, thirty-nine months from July 14, 2017 to October 20, 2020, on the straight-line basis. As described in Note F below, additional transaction costs of $12,000 were incurred with the Amendment and will be written off over the period of the date of the Amendment, January 30, 2018, to October 15, 2020. At March 31, 2018 transaction costs of $64,000 ($23,000 in 2018 and $41,000 in the second half of 2017), have been amortized and included in the Condensed Consolidated Statements of Operations in Interest and Other Expenses. At March 31, 2018 and December 31, 2017, unamortized transaction costs of $235,000 and $246,000, respectively, have been netted against the outstanding Secured Debt balance on the Condensed Consolidated Balance Sheets. As discussed in Note F below, interest payable on the Secured Debt is now due at loan maturity, October 15, 2020, and, at March 31, 2018 and December 31, 2017, accrued interest of $104,000 and $68,000, respectively, has been included in the Secured Debt balance on the Condensed Consolidated Balance Sheets. The interest on the secured debt ($36,000 in 2018 and $68,000 in the second half of 2017) has been included in the Condensed Consolidated Statements of Operations in Interest and Other Expenses.

A summary of the Secured Debt activity is as follows (000’s):

	March 31, 2018			December 31, 2017

Secured Debt	$	2,427		$	2,427
Transaction costs		(299	)		(287	)
	$	2,128		$	2,140
Amortization		64			41
	$	2,192		$	2,181
Accrued interest		104			68
	$	2,296		$	2,249

The secured loan bears interest at 6% per annum, with interest payable quarterly (now due at loan maturity see Note F below) and is secured by a security interest in all of our assets. As part of the Agreement, the Company and Brookstone entered into a Registration Rights Agreement granting Brookstone certain demand and piggyback registration rights. A provision in the Agreement entered into with Brookstone also requires the Company to nominate two candidates for a director position that have been recommended by Brookstone as long as Brookstone beneficially owns over 20% of the Company’s outstanding common stock and to nominate one candidate for a director position that has been recommended by Brookstone as long as Brookstone beneficially owns over 5% but less than 20% of the Company’s outstanding common stock.

On April 18, 2017, the Company and Computershare Trust Company, N.A., as Rights Agent (the “Rights Agent”) entered into Tax Benefit Preservation Plan Agreement (the “Plan”), dated as of April 18, 2017, between the Company and the Rights Agent, as described in the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on April 19, 2017. The Plan is intended to act as a deterrent to any person (together with all affiliates and associates of such person) acquiring “beneficial ownership” (as defined in the Plan) of 4.99% or more of the outstanding shares of Common Stock without the approval of the Board (an “Acquiring Person”), in an effort to protect against a possible limitation on the Company’s ability to use its net operating loss carryforwards. The Board, in accordance with the Plan, granted an Exemption to Brookstone with respect to the share acquisition described above, and Brookstone’s acquisition of 5,041,197 shares of the Company’s Common Stock from Biotechnology Value Fund affiliated entities, making Brookstone an Exempt Person in respect of such transactions.

Note F.

RELATED PARTY TRANSACTION - DEFERRAL OF SECURED DEBT INTEREST PAYMENTS AND ISSUANCE OF WARRANTS TO PURCHASE SHARES OF THE ANY’S COMMON STOCK

As described in our Current Report on Form 8-K filed with the Securities and Exchange Commission on February 1, 2018, on January 30, 2018, the Company entered into the First Amendment to Securities Purchase, Loan and Security Agreement (the “Amendment”) with BP Peptides, LLC (“Brookstone"). Brookstone currently owns approximately 34.1% of our outstanding common stock. Under the original Agreement (see Note E above), interest on the Secured Debt was payable quarterly. The Amendment defers the payment of interest until the Secured Debt’s maturity, October 15, 2020. In consideration for the deferral, the Company issued a Warrant to Brookstone to purchase up to 6,321,930 shares of the Company’s Common Stock with an exercise price of $.075 per share. The warrant expires October 15, 2025 and provides for quarterly vesting of shares in amounts approximately equal to the amount of quarterly interest payable that would have been payable under the Agreement, converted into shares at $0.75. At March 31, 2018, 984,301 shares are fully vested and exercisable.

The fair value of the Warrants was determined to be $43,000. The fair value of the Warrants will be amortized over the deferral period, January 30, 2018 to October 15, 2020, on the straight-line basis, as additional interest expense. Amortization expenses totaled $2,000 at March 31, 2018 and is included in Interest and other expenses, net, in the Condensed Consolidated Statement of Operations.

Note G.

SUBSEQUENT EVENT - LIPIMETIX DEVELOPMENT, INC. LICENSE AGREEMENT

As described in our Current Report on Form 8-K filed with the Securities and Exchange Commission on May 7, 2018, on May 2, 2018, our JV, LipimetiX Development, Inc., entered into a License Agreement (the “Sub-License”) with Anji Pharmaceuticals Inc. (“ANJI") to sublicense, under its Exclusive License Agreement with the UAB Research Foundation, the use of the JV’s AEM-28 and analogs intellectual property in the Territory of the People’s Republic of China, Taiwan and Hong Kong (the “Territory”). The Sub-License calls for an initial payment of $2,000,000, payment of a royalty on future Net Sales in the Territory and cash milestone payments based on future clinical/regulatory events. ANJI will perform all development activities allowed under the Sub-License in the Territory at its sole cost and expense. As described in Note B above, at March 31, 2018, JV net losses exceeded the JV capital accounts and all losses were being allocated to the Company. Revenue from the initial license payment, when recorded, is expected to reduce the amount of JV net losses previously allocated to the Company.

A copy of the UAB Research Foundation Exclusive License Agreement was attached as Exhibit 10.7 to the Company’s Quarterly Report on Form 10-Q for the period ending June 30, 2012 filed with Securities and Exchange Commission (‘SEC”) on August 10, 2012. A copy of the First Amendment and Consent to Assignment of the Exclusive License Agreement was attached as Exhibit 10.3 to the Company’s Quarterly Report on Form 10-Q for the period ending June 30, 2012 filed with the SEC on August 10, 2012. The Second Amendment to the Exclusive License Agreement was attached as Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the SEC on January 30, 2015.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

The following is management’s discussion of significant events in the three-month period ended March 31, 2018 and factors that affected our interim financial condition and results of operations. This should be read in conjunction with our “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and “Risk Factors” included in our Annual Report on Form 10-K for the year ended December 31, 2017.

Description of the Business

On August 3, 2012, we entered into a joint venture, LipimetiX Development, LLC, (now LipimetiX Development, Inc.), (the “JV”), to develop Apo E mimetic peptide molecule AEM-28 and its analogs. The JV has a development plan to pursue regulatory approval of AEM-28 or an analog, as treatment for Homozygous Familial Hypercholesterolemia, other hyperlipidemic indications, and acute coronary syndrome/atherosclerosis regression. The initial AEM-28 development plan extended through Phase 1a and 1b/2a clinical trials and was completed in the fourth quarter of 2014. The clinical trials had a safety primary endpoint and an efficacy endpoint targeting reduction of cholesterol and triglycerides.

The JV and the Company are exploring fundraising, partnering or licensing, to obtain additional funding to continue development activities and operations.

Description of Current Peptide Drug Candidates.

Apo E Mimetic Peptide Molecule – AEM-28 and its analogs

Critical Accounting Policies

Our critical accounting policies are those that affect or could affect our financial statements materially and involve a significant level of judgment by management. The accounting policies and related risks described in our Annual Report on Form 10-K, filed with the Securities and Exchange Commission on February 28, 2018, for the year ended December 31, 2017 are those that depend most heavily on these judgments and estimates. As of March 31, 2018, there have been no material changes to any of the critical accounting policies contained in our Annual Report for the year ended December 31, 2017.

Results of Operations Comparing Three-Month Period Ended March 31, 2018 to the Corresponding Period in 2017.

General and Administrative (“G&A”) Expenses: G&A expenses related to our ongoing operations were $229,000 in the first quarter of 2018 compared to $113,000 in the first quarter of 2017. Administration expenses increased primarily due to professional fees (legal and accounting) due to business transaction activity and the lack of audit fees in the first quarter of 2017, as the audit of the 2016 financial statements did not commence until the third quarter of 2017.

Research and Development Expenses: Research and development expenses were $301,000 for the first quarter of 2018 compared to $267,000 for the first quarter of 2017. Our research and development expenses continue to reflect reduced spending as our development activities of AEM-28 and its analogs were limited, as we attempt to obtain additional funding.

Net Loss attributable to Capstone Therapeutics stockholders: We incurred a net loss in the first quarter of 2018 of $.6 million compared to a net loss of $.4 million in the first quarter of 2017. Net losses were comparable between periods after considering the above comments. Our operations and the development activities of AEM-28 and its analogs were limited, as we attempt to obtain additional funding.

Liquidity and Capital Resources

With the sale of our Bone Device Business in November 2003, we sold all of our revenue producing operations. Since that time, we have primarily relied on our cash and investments to finance all our operations, the focus of which has been research and development of our product candidates.

On August 3, 2012, we entered into a joint venture, to develop Apo E mimetic peptide AEM-28 and its analogs. We contributed $6.0 million and through March 31, 2018 we have loaned an additional $1.6 million to the JV. The JV raised $1,012,000 ($946,000 net of issuance costs) in the JV’s Series B-1 Preferred Stock and Warrant offering in August 2016. As described in Note E to the Financial Statements included in this Quarterly Report on Form 10-Q, the Company on July 14, 2017, raised $3,440,000, with net proceeds of approximately $2,074,000, after paying off the Convertible Promissory Notes described in Note D to the Financial Statements included in this Quarterly Report on Form 10-Q, and transaction costs of $287,000. At March 31, 2018, we had cash and cash equivalents of $805,000, of which $300,000 is held by our JV. As disclosed in Note G to the Financial Statements included in this Quarterly Report on Form 10-Q, on May 2, 2018, our JV entered into a License Agreement which will result in the receipt of a $2,000,000 nonrefundable payment.

We intend to continue limiting our internal operations to a virtual operating model in 2018; however, without additional funding, we will also limit the development activities of AEM-28 and its analogs. Lack of additional funding for development activities of AEM-28 and its analogs could would impair our ability to continue our current operations as planned.

Funding permitting, our planned operations in 2018 consist of continuing monitoring and participating in the management of the JV’s development activities.

Our future research and development and other expenses will vary significantly from prior periods and depend on the Company’s decisions on future JV operations and obtaining additional funding.

We will require additional funds if we choose to extend the development of AEM-28 and its analogs. We cannot currently predict the amount of funds that will be required if we choose to extend the development activities of AEM-28 and its analogs and to continue operations. In any event, to complete the clinical trials and supporting research and production efforts necessary to obtain FDA or comparable foreign agencies’ approval for product candidates would require us to obtain additional capital. New sources of funds, including raising capital through the sales of our debt or equity securities, joint venture or other forms of joint development arrangements, sales of development rights, or licensing agreements, may not be available or may only be available on terms that would have a material adverse impact on our existing stockholders’ interests.

As discussed in Note E to the Financial Statement included in this Quarterly Report on Form 10-Q, on July 14, 2017, the Company received a secured loan of $2,427,500, due October 15, 2020, from BP Peptides, LLC, an entity that at March 31, 2018 owns approximately 34.1% of the Company’s common stock. Interest on the secured loan, at a rate of 6% per annum, is payable on the maturity date of the secured loan.

Item 4. Controls and Procedures

Disclosure Controls and Procedures

Our management, with the participation of our principal executive officer and principal financial and accounting officer, has reviewed and evaluated our disclosure controls and procedures (as defined in the Securities Exchange Act Rule 13a-15(e)) as of the end of the period covered by this Form 10-Q. Based on that evaluation, our management, including our principal executive officer and principal financial and accounting officer, has concluded that our disclosure controls and procedures were effective as of the end of the period covered by this Form 10-Q in ensuring that information required to be disclosed in the reports that we file or submit under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms and is accumulated and communicated to management, including our principal executive officer and principal financial and accounting officer, as appropriate, to allow timely decisions regarding required disclosure.

Internal Control Over Financial Reporting

There were no changes in our internal control over financial reporting during the fiscal quarter to which this report relates that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Part II – Other Information

Item 1. Legal Proceedings

None

Item 6. Exhibits

See the Exhibit Index following this report.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

CAPSTONE THERAPEUTICS CORP.
(Registrant)

Signature	Title	Date

/s/ John M. Holliman, III	Chairman and Chief Executive Officer	May 11, 2018
John M. Holliman, III	(Principal Executive Officer)


/s/ Les M. Taeger	Senior Vice President and Chief	May 11, 2018
Les M. Taeger	Financial Officer
	(Principal Financial and Accounting Officer)

Capstone Therapeutics Corp.

(the “Company”)

Exhibit Index to Quarterly Report on Form 10-Q

For the Quarterly Period Ended March 31, 2018

No.	Description	Incorporated by Reference To:	Filed Herewith
10.1	License Agreement dated May 2, 2018 by and between LipimetiX Development, Inc. and Anji Pharmaceuticals Inc	Exhibit 10.1 to our Current Report on Form 8-K filed with the Securities and Exchange Commission on May 7, 2018
31.1	Certification of Principal Executive Officer Pursuant to Securities Exchange Act Rule 13a-14(a), as amended.		X
31.2	Certification of Principal Financial and Accounting Officer Pursuant to Securities Exchange Act Rule 13a-14(a), as amended.		X
32	Certification of Principal Executive Officer and Principal Financial and Accounting Officer Pursuant to 18 U.S.C. Section 1350.*
101	The following financial information from our Quarterly Report on Form 10-Q for the first quarter of fiscal year 2018, filed with the SEC on May 11, 2018 formatted in Extensible Business Reporting Language (XBRL): (i) the Condensed Consolidated Balance Sheets as of March 31, 2018 and December 31, 2017, (ii) the Condensed Consolidated Statements of Operations for the three months ended March 31, 2018 and 2017 (iii) the Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2018 and 2017, and (iv) Notes to Unaudited Condensed Consolidated Financial Statements.		X


	* Furnished herewith

EX-31.1 2 exh_311.htm EXHIBIT 31.1

Exhibit 31.1

CERTIFICATION

I, John M. Holliman, III certify that:

I have reviewed this quarterly report on Form 10-Q of Capstone Therapeutics Corp.;

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 11, 2018

By: /s/ John M. Holliman, III

John M. Holliman, III
Chairman and Chief Executive Officer

(Principal Executive Officer)

EX-31.2 3 exh_312.htm EXHIBIT 31.2

Exhibit 31.2

CERTIFICATION

I, Les M. Taeger, certify that:

I have reviewed this quarterly report on Form 10-Q of Capstone Therapeutics Corp.;

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 11, 2018

By: /s/ Les M. Taeger

Les M. Taeger
Senior Vice President and Chief Financial Officer

(Principal Financial and Accounting Officer)

EX-32 4 exh_32.htm EXHIBIT 32

Exhibit 32

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Capstone Therapeutics Corp. (the “Company”) on Form 10-Q for the period ended March 31, 2018 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of John M. Holliman, III, Executive Chairman and Principal Executive Officer of the Company, and Les M. Taeger, Senior Vice President and Chief Financial Officer, and Principal Financial and Accounting Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that to the best of his knowledge:

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: May 11, 2018

/s/ John M. Holliman, III

John M. Holliman, III

Chairman and Chief Executive Officer

(Principal Executive Officer)

/s/ Les M. Taeger

Les M. Taeger

Senior Vice President and Chief Financial Officer

(Principal Financial and Accounting Officer)

EX-101.INS 5 caps-20180331.xml XBRL INSTANCE FILE 0000887151 2017-01-01 2017-03-31 0000887151 2018-01-01 2018-03-31 0000887151 2016-03-01 2016-03-31 0000887151 2018-03-31 0000887151 2018-05-01 0000887151 2016-05-10 2016-06-01 0000887151 2017-07-02 2017-07-14 0000887151 2017-07-14 0000887151 2012-08-01 2012-08-03 0000887151 2017-08-01 2017-08-11 0000887151 2017-08-02 2017-08-11 0000887151 2012-08-03 0000887151 2012-08-04 2018-03-31 0000887151 2016-08-25 0000887151 2017-08-31 0000887151 2017-12-31 0000887151 2016-12-31 0000887151 2017-03-31 0000887151 caps:BrookstoneMember 2017-07-01 2017-07-14 0000887151 caps:SeriesB2PreferredStocksMember 2017-08-02 2017-08-11 0000887151 caps:SeriesB2PreferredStockMember 2016-08-31 0000887151 caps:LipimetixMember caps:OwnershipAsConvertedMember 2018-03-31 0000887151 us-gaap:RevolvingCreditFacilityMember 2018-03-31 0000887151 caps:SeriesB2PreferredStockMember 2016-08-01 2016-08-25 0000887151 caps:SeriesB2PreferredStockMember 2016-08-25 0000887151 us-gaap:CommonStockMember 2018-03-31 0000887151 caps:NonVotingPreferredOwnershipUnitsMember 2012-08-03 0000887151 us-gaap:MinimumMember 2016-03-01 2016-03-31 0000887151 us-gaap:MaximumMember 2016-03-01 2016-03-31 0000887151 caps:SeriesB1AndB2PreferredStockMember 2012-08-01 2012-08-03 0000887151 caps:SeriesB2PreferredStockMember 2017-08-02 2017-08-11 0000887151 caps:LipimetixMember caps:OwnershipAsConvertedMember 2012-08-03 0000887151 caps:LipimetixMember 2012-08-01 2012-08-03 0000887151 caps:ExclusiveLicenseAgreementMember 2017-08-01 2017-08-11 0000887151 caps:ExclusiveLicenseAgreementMember us-gaap:MinimumMember 2017-08-01 2017-08-11 0000887151 caps:ExclusiveLicenseAgreementMember us-gaap:MaximumMember 2017-08-01 2017-08-11 0000887151 caps:SeriesB1PreferredStockMember 2016-01-01 2016-12-31 0000887151 caps:SeriesB1PreferredStockMember 2018-03-31 0000887151 caps:SeriesB1PreferredStockMember 2017-08-01 2017-08-31 0000887151 caps:SeriesB1PreferredStockMember 2017-07-01 2017-09-30 0000887151 caps:SeriesB1PreferredStockMember 2017-03-31 0000887151 caps:LipimetixMember 2018-01-01 2018-03-31 0000887151 us-gaap:PreferredStockMember 2018-03-31 0000887151 caps:SeriesB1PreferredStockMember 2016-08-25 0000887151 us-gaap:NoncontrollingInterestMember 2012-08-04 2018-03-31 0000887151 caps:LipimetixAustraliaPtyLtdMember us-gaap:MinimumMember 2014-03-01 2014-03-31 0000887151 caps:LipimetixAustraliaPtyLtdMember us-gaap:MaximumMember 2014-03-01 2014-03-31 0000887151 us-gaap:OtherCurrentAssetsMember us-gaap:ResearchMember 2018-03-31 0000887151 us-gaap:ConvertibleNotesPayableMember 2015-12-11 0000887151 us-gaap:ConvertibleNotesPayableMember 2017-07-14 0000887151 caps:BrookstoneMember 2017-07-14 0000887151 us-gaap:MinimumMember caps:BrookstoneMember 2017-04-18 0000887151 caps:SeriesB2PreferredStocksMember 2017-07-01 2017-07-14 0000887151 caps:SeriesB2PreferredStocksMember 2017-08-01 2017-08-31 0000887151 us-gaap:OtherCurrentAssetsMember us-gaap:ResearchMember 2017-12-31 0000887151 caps:LipimetixAustraliaPtyLtdMember 2018-01-01 2018-03-31 0000887151 caps:LipimetixAustraliaPtyLtdMember 2017-01-01 2017-03-31 0000887151 caps:MrhollimanMember 2017-10-02 2017-10-27 0000887151 caps:OwnershipasconvertedincludingoptionsandwarrantsMember 2017-10-02 2017-10-27 0000887151 caps:SeriesB1PreferredStockMember 2016-08-01 2016-08-25 0000887151 caps:BrookstoneMember 2017-07-02 2017-07-14 0000887151 caps:BrookstoneMember 2018-03-31 0000887151 caps:BrookstoneMember 2018-01-01 2018-03-31 0000887151 caps:SeriesB2PreferredStockMember 2012-08-01 2012-08-03 0000887151 caps:BrookstoneMember 2018-01-30 0000887151 caps:BrookstoneMember 2018-01-01 2018-01-30 0000887151 caps:InterestAndOtherExpensesMember 2018-01-01 2018-03-31 0000887151 caps:LipimetixMember us-gaap:SubsequentEventMember 2018-04-29 2018-05-02 0000887151 caps:BrookstoneMember 2018-03-01 2018-03-31 0000887151 caps:BrookstoneMember 2017-07-01 2017-12-31 0000887151 us-gaap:SecuredDebtMember 2018-03-31 0000887151 us-gaap:SecuredDebtMember 2017-12-31 0000887151 caps:InterestAndOtherExpensesMember 2018-03-01 2018-03-31 0000887151 caps:InterestAndOtherExpensesMember 2017-07-01 2017-12-31 0000887151 caps:BrookstoneMember 2017-12-31 0000887151 caps:BrookstoneMember us-gaap:SecuredDebtMember 2018-01-01 2018-01-30 0000887151 us-gaap:ConvertibleNotesPayableMember 2015-12-01 2015-12-11 0000887151 caps:BrookstoneMember us-gaap:SecuredDebtMember 2018-01-01 2018-03-31 0000887151 caps:VotingCommonOwnershipUnitsMember 2012-08-03 0000887151 caps:OwnershipAsConvertedMember 2018-01-01 2018-03-31 xbrli:shares iso4217:USD iso4217:USD xbrli:shares iso4217:AUD xbrli:pure 10-Q false 2018-03-31 2018 Q1 Capstone Therapeutics Corp. 0000887151 --12-31 Smaller Reporting Company CAPS 54385411

1275000

805000

98000

76000

1373000

881000

196000

157000

1569000

1038000

197000

203000

2000

3000

199000

206000

190468000

190470000

-191374000

-191961000

-879000

-1464000

-879000

-1464000

1569000

1038000

27000

2296000

2249000

229000

301000

530000

-60000

-590000

-3000

-587000

0.01

54385000

-587000

113000

267000

380000

-15000

-395000

-8000

-387000

0.01

40885000

-387000

44000

39000

2000

75000

6000

-212000

-470000

-212000

-470000

698000

486000

-44000

-10000

12000

1000

2074000

3440000

1000000

93458

946000

0.6

1600000

6000000

1012000

946000

946000 0

1000000

6000000

600000 5000000

5000000

1500000

120000

0.6 0.64 0.6 0.622

3500000

1000000

93458

1000000

0.6975

400000 0.4

378000

1000000

0.05 0.03 25000 50000

500000

1000000

63000 80000

10000

60000

20000

160000

300000

150000

250000

50000

300000

667000

378000

1660000

946000

60000

427000 10078000 427000 8466000

667000000

0.435

0.45

46000

1000000

0.05

79000

1000000

1012500

13500000

2427500

0.06

0.0499

0.0005

150000000

54385411

59000

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 2.25pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in"> <b><font style="FONT-SIZE: 10pt">Description of the Business</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">Capstone Therapeutics Corp. (the “Company”, “we”, “our” or “us”) is a biotechnology company committed to developing a pipeline of novel peptides and other molecules aimed at helping patients with under-served medical conditions. Previously, we were focused on the development and commercialization of two product platforms: AZX100 and Chrysalin (TP508). In 2012, we terminated the license for Chrysalin (targeting orthopedic indications). In 2014, we terminated the license for AZX100 (targeting dermal scar reduction). Capstone no longer has any rights to or interest in Chrysalin or AZX100.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">On August 3, 2012, we entered into a joint venture, LipimetiX Development, LLC, (now LipimetiX Development, Inc.), (the “JV”), to develop Apo E mimetic peptide molecule AEM-28 and its analogs. The JV has a development plan to pursue regulatory approval of AEM-28, or an analog, as treatment for Homozygous Familial Hypercholesterolemia, other hyperlipidemic indications, and acute coronary syndrome/atherosclerosis regression. The initial AEM-28 development plan extended through Phase 1a and 1b/2a clinical trials and was completed in the fourth quarter of 2014. The clinical trials had a safety primary endpoint and an efficacy endpoint targeting reduction of cholesterol and triglycerides.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">In early 2014, the JV received allowance from regulatory authorities in Australia permitting the JV to proceed with the planned clinical trials. The Phase 1a clinical trial commenced in Australia in April 2014 and the Phase 1b/2a clinical trial commenced in Australia in June 2014. The clinical trials for AEM-28 were randomized, double-blinded, placebo-controlled studies to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of six escalating single doses (Phase 1a in healthy patients with elevated cholesterol) and multiple ascending doses of the three highest doses from Phase 1a (Phase 1b/2a in patients with hypercholesterolemia and healthy volunteers with elevated cholesterol and high Body Mass Index). The Phase 1a clinical trial consisted of 36 patients and the Phase 1b/2a consisted of 15 patients. Both clinical trials were completed in 2014 and the Medical Safety Committee, reviewing all safety-related aspects of the clinical trials, observed a generally acceptable safety profile. As first-in-man studies, the primary endpoint was safety; yet efficacy measurements analyzing pharmacodynamics yielded statistical significance in the pooled dataset favoring AEM-28 versus placebo in multiple lipid biomarker endpoints.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">Concurrent with the clinical development activities of AEM-28, the JV has performed pre-clinical studies that have identified analogs of AEM-28, and new formulations, that have the potential of increased efficacy, higher human dose toleration and an extended composition of matter patent life (application filed with the U.S. Patent and Trademark Office in 2014).</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The JV and the Company are exploring fundraising, partnering or licensing, to obtain additional funding to continue development activities and operations.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The JV and the Company do not have sufficient funding at this time to continue additional material development activities. The JV may conduct future clinical trials in Australia, the USA, and other regulatory jurisdictions if regulatory approvals, additional funding, and other conditions permit.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The Company, funding permitting, intends to continue limiting its internal operations to a virtual operating model while monitoring and participating in the management of JV’s development activities.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <b><font style="FONT-SIZE: 10pt">Description of Current Peptide Drug Candidates.</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <b><font style="FONT-SIZE: 10pt"> </font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <u><font style="FONT-SIZE: 10pt">Apo E Mimetic Peptide Molecule  AEM-28 and its analogs</font></u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">Apolipoprotein E is a 299 amino acid protein that plays an important role in lipoprotein metabolism. Apolipoprotein E (Apo E) is in a class of protein that occurs throughout the body. Apo E is essential for the normal metabolism of cholesterol and triglycerides. After a meal, the postprandial (or post-meal) lipid load is packaged in lipoproteins and secreted into the blood stream. Apo E targets cholesterol and triglyceride rich lipoproteins to specific receptors in the liver, decreasing the levels in the blood. Elevated plasma cholesterol and triglycerides are independent risk factors for atherosclerosis, the buildup of cholesterol rich lesions and plaques in the arteries. AEM-28 is a 28 amino acid mimetic of Apo E and AEM-28 analogs are also 28 amino acid mimetics of Apo E (with an aminohexanoic acid group and a phospholipid). Both contain a domain that anchors into a lipoprotein surface while also providing the Apo E receptor binding domain, which allows clearance through the heparan sulfate proteoglycan (HSPG) receptors (Syndecan-1) in the liver. AEM-28 and its analogs, as Apo E mimetics, have the potential to restore the ability of these atherogenic lipoproteins to be cleared from the plasma, completing the reverse cholesterol transport pathway, and thereby reducing cardiovascular risk. This is an important mechanism of action for AEM-28 and its analogs. Atherosclerosis is the major cause of cardiovascular disease, peripheral artery disease and cerebral artery disease, and can cause heart attack, loss of limbs and stroke. Defective lipid metabolism also plays an important role in the development of adult onset diabetes mellitus (Type 2 diabetes), and diabetics are particularly vulnerable to atherosclerosis, heart and peripheral artery diseases. Our joint venture has an Exclusive License Agreement with the University of Alabama at Birmingham Research Foundation for a broad domain of Apo E mimetic peptides, including AEM-28 and its analogs.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <b><font style="FONT-SIZE: 10pt">Company History</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">Prior to November 2003, we developed, manufactured and marketed proprietary, technologically advanced orthopedic products designed to promote the healing of musculoskeletal bone and tissue, with particular emphasis on fracture healing and spine repair. Our product lines, which included bone growth stimulation and fracture fixation devices, are referred to as our “Bone Device Business.” In November 2003, we sold our Bone Device Business.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">In August 2004, we purchased substantially all of the assets and intellectual property of Chrysalis Biotechnology, Inc., including its exclusive worldwide license for Chrysalin, a peptide, for all medical indications. Subsequently, our efforts were focused on research and development of Chrysalin with the goal of commercializing our products in fresh fracture healing. (In March 2012, we returned all rights to the Chrysalin intellectual property and no longer have any interest in, or rights to, Chrysalin.)</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">In February 2006, we purchased certain assets and assumed certain liabilities of AzERx, Inc. Under the terms of the transaction, we acquired an exclusive license for the core intellectual property relating to AZX100, an anti-fibrotic peptide. In 2014, we terminated the License Agreement with AzTE (Licensor) for the core intellectual property relating to AZX100 and returned all interest in and rights to the AZX100 intellectual property to the Licensor.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">On August 3, 2012, we entered into a joint venture (As described in Note B below) to develop Apo E mimetic peptide molecule AEM-28 and its analogs.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">Our development activities represent a single operating segment as they shared the same product development path and utilized the same Company resources. As a result, we determined that it is appropriate to reflect our operations as one reportable segment.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">OrthoLogic Corp. commenced doing business under the trade name of Capstone Therapeutics on October 1, 2008, and we formally changed our name from OrthoLogic Corp. to Capstone Therapeutics Corp. on May 21, 2010.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">In these notes, references to “we”, “our”, “us”, the “Company”, “Capstone Therapeutics”, “Capstone”, and “OrthoLogic” refer to Capstone Therapeutics Corp. References to our joint venture or “JV”, refer to LipimetiX Development, Inc. (formerly LipimetiX Development, LLC).</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <b><font style="FONT-SIZE: 10pt">Basis of presentation, Going Concern, and Management’s Plans.</font></b> <font style="FONT-SIZE: 10pt">The accompanying financials statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <font style="FONT-SIZE: 10pt"><font style="FONT-SIZE: 10pt"><font style="FONT-SIZE: 10pt"></font></font></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> Management has determined that the Company will require additional capital above its current cash and working capital balances to further develop AEM-28 and its analogs or to continue operations. Accordingly, the Company has significantly reduced its development activities. The Company’s corporate strategy is to raise funds by possibly engaging in a strategic/merger transaction or conducting a private or public offering of debt or equity securities for capital. In August 2016, the Company’s joint venture raised net funds of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">946,000</font> in a Series B-1 Preferred Stock and Warrant offering. As described in Note E below, the Company, on July 14, 2017, raised $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">3,440,000</font>, with net proceeds of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2,074,000</font>, after paying off the Convertible Promissory Notes described in Note D below, and transaction costs of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">287,000</font>. As discussed in Note B below, in August 2017, the Company used $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,000,000</font> of the net proceeds to purchase <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 93,458</font> shares of LipimetiX Development, Inc.’s Series B-2 Preferred Stock. Additionally, as disclosed in Note G below, on May 2, 2018, LipimetiX Development, Inc. entered into a License Agreement which will result in the receipt of a $2,000,000 nonrefundable payment. The additional funds has alleviated the substantial doubt about the entity’s ability to continue as a going concern; however, additional funds will be required for the joint venture to reach its development goals and for the Company to continue its planned operations.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">In the opinion of management, the unaudited condensed interim financial statements include all adjustments necessary for the fair presentation of our financial position, results of operations, and cash flows, and all adjustments were of a normal recurring nature. The results of operations for the interim periods are not necessarily indicative of the results to be expected for the complete fiscal year. The financial statements include the consolidated results of Capstone Therapeutics Corp. and our approximately <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 60</font>% owned subsidiary, LipimetiX Development, Inc. Intercompany transactions have been eliminated.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted pursuant to Securities and Exchange Commission rules and regulations, although we believe that the disclosures herein are adequate to make the information presented not misleading. These unaudited condensed financial statements should be read in conjunction with the financial statements and the notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2017. Information presented as of December 31, 2017 is derived from audited financial statements.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <b><font style="FONT-SIZE: 10pt">Use of estimates.</font></b> <font style="FONT-SIZE: 10pt">The preparation of financial statements in accordance with accounting principles generally accepted in the United States of America requires that management make a number of assumptions and estimates that affect the reported amounts of assets, liabilities, and expenses in our financial statements and accompanying notes. Management bases its estimates on historical experience and various other assumptions believed to be reasonable. Although these estimates are based on management’s assumptions regarding current events and actions that may impact the Company in the future, actual results may differ from these estimates and assumptions.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">Our significant estimates include income taxes, contingencies, accounting for stock-based compensation, and accounting for the Australian refundable research and development tax credit.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> </div> <font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><strong>Joint Venture Accounting.</strong></font> <font style="FONT-SIZE: 10pt">The Company entered into a joint venture in which it has contributed $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">6,000,000</font>, and the noncontrolling interests have contributed certain patent license rights. As discussed in Note B below, in August 2017, the Company purchased <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 93,458</font> shares of LipimetiX Development, Inc.’s Series B-2 Preferred Stock for $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,000,000</font>. Neither the Company nor the noncontrolling interests have an obligation to contribute additional funds to the joint venture or to assume any joint venture liabilities or to provide a guarantee of either joint venture performance or any joint venture liability. The financial position and results of operations of the joint venture are presented on a consolidated basis with the financial position and results of operations of the Company. Intercompany transactions have been eliminated. Joint venture losses were recorded on the basis of common ownership equity interests until common ownership equity was reduced to $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0</font>. Subsequent joint venture losses were allocated to the Series A preferred ownership. Subsequent to March 31, 2013, all joint venture losses had been allocated to the Company. On August 25, 2016, the JV raised $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,012,000</font> ($<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">946,000</font> net of issuance costs) in a Series B-1 Preferred Stock and Warrant offering and in 2016, $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">946,000</font> in losses were allocated to the Series B-1 Preferred Stock ownership interests. As of March 31, 2018, losses incurred by the JV exceeded the capital accounts of the JV. The Company has a revolving loan agreement with the joint venture and advanced the joint venture funds for operations in an amount of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,600,000</font>, with the net amount due December 31, 2016. As described in Note B below, the due date of the revolving loan has been extended to July 15, 2020, with early payment required upon certain additional funding of the joint venture by non-affiliated parties. Losses incurred by the joint venture in excess of the capital accounts of the joint venture will be allocated to the Company to the extent of net outstanding advances.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

287000

93458

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <strong><font style="FONT-SIZE: 10pt">Note B. JOINT VENTURE FOR DEVELOPMENT OF APO E MIMETIC PEPTIDE MOLECULE AEM-28 AND ANALOGS</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <strong><font style="FONT-SIZE: 10pt"> </font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">On August 3, 2012, we entered into a Contribution Agreement with LipimetiX, LLC to form a joint venture, LipimetiX Development, LLC (“JV”), to develop Apo E mimetic molecules, including AEM-28 and its analogs. In June 2015, the JV converted from a limited liability company to a corporation, LipimetiX Development, Inc. The Company contributed $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">6</font> million, which included $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1</font> million for <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 600,000</font> voting common ownership units (now common stock), representing <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 60</font>% ownership in the JV, and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">5</font> million for <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 5,000,000</font> non-voting preferred ownership units (now Series A Preferred Stock), which have preferential distribution rights. On March 31, 2016, the Company converted <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 1,500,000</font> shares of its preferred stock into <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 120,000</font> shares of common stock, increasing its common stock ownership from <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 60</font>% to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 64</font>%. On August 11, 2017, the remaining $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">3,500,000</font> (<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">3,500,000</font> shares) of Series A preferred stock became convertible, at the Company’s option, into common stock, at the lower of the Series B Preferred Stock Conversion Price, as may be adjusted for certain events, or the price of the next LipimetiX Development, Inc. financing, exceeding $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,000,000</font> on independently set valuation and terms. On August 11, 2017, the Company purchased <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 93,458</font> shares of LipimetiX Development, Inc.’s Series B-2 Preferred Stock for $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,000,000</font> (LipimetiX Development, Inc. incurred $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">15,000</font> in transaction costs as part of the Series B-2 Preferred Stock issuance, which was been shown in our Annual Report on Form 10-K for the year ended December 31, 2017 filed with the Securities and Exchange Commission on February 28, 2018, as a reduction of Additional Paid in Capital on the Consolidated Statements of Changes in Equity and a cash flow provided by financing activities in the Consolidated Statements of Cash Flows at December 31, 2017). As discussed below, the JV Series B-1 and B-2 Preferred Stock issuances, because of the participating and conversion features of the preferred stock, effectively changes the Company’s ownership in the JV to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 62.2</font>%. With the Series B-1 and B-2 Preferred Stock on an as-converted basis, and the Company converting its Series A Preferred Stock to common stock, the Company’s ownership would change to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 69.75</font>%. The JV 2016 Equity Incentive Plan has <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 83,480</font> shares of the JV’s common stock available to grant, of which, at March 31, 2018, options to purchase JV common stock shares totaling <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 81,479</font> have been granted. All options were granted with an exercise price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.07</font>, vest <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 50</font>% on the date of grant and monthly thereafter in equal amounts over a twenty-four-month period and are exercisable for ten years from the date of grant. If all stock available to grant in the JV 2016 Equity Incentive Plan were granted and exercised, and the Series B-1 Preferred Stock Warrants were exercised, the Company’s fully diluted ownership (on an as-converted basis) would be approximately <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 65.11</font>%. On October 27, 2017 the Board granted Mr. Holliman an option to purchase<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">14,126</font> shares of the LipimetiX Development, Inc. Series B-2 Preferred Stock it currently owns, at an exercise price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">10.70</font> per share, subject to adjustment and other terms consistent with the Series B-2 Preferred Stock. The option is exercisable for a five-year period from the date of grant. If exercised, this option would reduce the Company’s fully diluted ownership (on an as-converted basis including assumed exercise of other options and warrants) to approximately <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 64.31</font>%.</font></div> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">LipimetiX, LLC was formed by the principals of Benu BioPharma, Inc. (“Benu”) and UABRF to commercialize UABRF’s intellectual property related to Apo E mimetic molecules, including AEM-28 and analogs. Benu is currently composed of Dennis I. Goldberg, Ph.D. and Eric M. Morrel, Ph.D. LipimetiX, LLC contributed all intellectual property rights for Apo E mimetic molecules it owned and assigned its Exclusive License Agreement between The University of Alabama at Birmingham Research Foundation (“UABRF”) and LipimetiX, LLC, for the UABRF intellectual property related to Apo E mimetic molecules AEM-28 and its analogs to the JV, in return for <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 400,000</font> voting common ownership units (now common stock), representing a <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 40</font>% ownership interest in the JV at formation, and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">378,000</font> in cash (for certain initial patent-related costs and legal expenses).</font></div> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">On August 25, 2016, LipimetiX Development, Inc. closed a Series B-1 Preferred Stock offering, raising funds of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,012,000</font> ($<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">946,000</font> net of issuance costs of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">66,000</font>). Individual accredited investors and management participated in the financing. This initial closing of the Series B-1 Preferred Stock offering resulted in the issuance of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 94,537</font> shares of preferred stock, convertible to an equal number of the JV’s common stock at the election of the holders and warrants to purchase an additional <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 33,088</font> shares of JV preferred stock, at an exercise price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">10.70</font>, with a ten-year term.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">As disclosed above, on August 11, 2017, the Company purchased 93,458 shares of LipimetiX Development, Inc.’s Series B-2 Preferred Stock for $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,000,000</font>.</font></div> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">Series B (B-1 and B-2) Preferred Stock is a participating preferred stock. As a participating preferred, the preferred stock will earn a 5% dividend, payable only upon the election by the JV or in liquidation. Prior to the JV common stock holders receiving distributions, the participating preferred stockholders will receive their earned dividends and payback of their original investment. Subsequently, the participating preferred will participate in future distributions on an equal “as-converted” share basis with common stock holders. The Series B Preferred Stock has “as-converted” voting rights and other terms standard to a security of this nature.</font></div> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The Exclusive License Agreement assigned by LipimetiX, LLC to the JV on formation of the JV, as amended, calls for payment of patent filing, maintenance and other related patent fees, as well as a royalty of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">3</font>% on Net Sales of Licensed Products during the Term of the Agreement. The Agreement terminates upon the expiration of all Valid Patent Claims within the Licensed Patents, which are currently estimated to expire between 2019 and 2035. The Agreement, as amended, also calls for annual maintenance payments of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">25,000</font>, various milestone payments of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">50,000</font> to $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">500,000</font> and minimum royalty payments of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">500,000</font> to $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,000,000</font> per year commencing on January 1 of the first calendar year following the year in which the First Commercial Sale occurs. UABRF will also be paid <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">5</font>% of Non-Royalty Income received.</font></div> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">Concurrent with entering into the Contribution Agreement and the First Amendment and Consent to Assignment of Exclusive License Agreement between LipimetiX, LLC, UABRF and the Company, the Company and LipimetiX, LLC entered into a Limited Liability Company Agreement for JV which established a Joint Development Committee (“JDC”) to manage JV development activities. Upon conversion by the JV from a limited liability company to a corporation, the parties entered into a Stockholders Agreement for the JV, and the JDC was replaced by a Board of Directors (JV Board). The JV Board is composed of three members appointed by the non-Company common stock ownership group, three members appointed by the Company and one member appointed by the Series B-1 Preferred Stockholders. Non-development JV decisions, including the issuance of new equity, incurrence of debt, entry into strategic transactions, licenses or development agreements, sales of assets and liquidation, and approval of annual budgets, will be decided by a majority vote of the common and Series B Preferred Stock (voting on an “as -converted” basis) stockholders.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The JV, on August 3, 2012, entered into a Management Agreement with Benu to manage JV development activities for a monthly fee of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">63,000</font> during the twenty-seven-month development period, and an Accounting Services Agreement with the Company to manage JV accounting and administrative functions. The services related to these agreements have been completed. New Management and Accounting Services Agreements were entered into effective June 1, 2016. The new monthly management fee is $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">80,000</font> and the new monthly accounting services fee was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">10,000</font>. However, no Management or Accounting Services fees are due or payable except to the extent funding is available, as unanimously approved by members of the JV Board of Directors and as reflected in the approved operating budget in effect at that time. In connection with the Series B-1 Preferred Stock issuance, Management Fees totaling $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">300,000</font>, of which $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">250,000</font> was charged to expense in 2016 and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">50,000</font> was charged to expense in the first quarter of 2017, and Accounting Fees totaling $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">60,000</font>, charged to expense in 2016, were paid in 2016. In August 2017 the Accounting Services Agreement monthly fee was increased to $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">20,000</font> and will thereafter be accrued but not payable, until certain levels of joint venture funding are obtained from non-affiliated parties. At March 31, 2018, accounting fees of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">160,000</font> were earned but unpaid. In August 2017, a Management Fee of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">300,000</font> was approved by the joint venture’s Board of Directors with $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">150,000</font> paid and charged to expense in the third quarter of 2017 and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">150,000</font> paid and expensed in the first quarter of 2018.</font></div> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The joint venture formation was as follows ($000’s):</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN: 0in 0in 0in 0.5in; WIDTH: 50%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="37%"> <div>Patent license rights</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,045</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="37%"> <div>Noncontrolling interests</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(667)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="37%"> <div>Cash paid at formation</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>378</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">Patent license rights were recorded at their estimated fair value and are being amortized on a straight-line basis over the key patent life of eighty months.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The financial position and results of operations of the joint venture are presented on a consolidated basis with the financial position and results of operations of the Company. Intercompany transactions have been eliminated. In the Company’s consolidated financial statements, joint venture losses were recorded on the basis of common ownership equity interests until common ownership equity was reduced to $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0</font>. Subsequent joint venture losses were being allocated to the Series A preferred ownership equity (<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">100</font>% Company). Subsequent to March 31, 2013, all joint venture losses had been allocated to the Company. On August 25, 2016 the JV raised $1,012,000, ($<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">946,000</font> net of issuance costs) in a Series B-1 Preferred Stock and Warrant offering and in 2016, $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">946,000</font> of losses were allocated to the Series B-1 Preferred Stock ownership interests. As of March 31, 2018, losses incurred by the JV exceeded the capital accounts of the JV. The Company has a revolving loan agreement with the joint venture, with the loan due December 31, 2016. In August 2017, the due date of the revolving loan was extended to July 15, 2020, with early payment required upon certain additional funding of the joint venture by non-affiliated parties. Subsequent to June 30, 2017, interest due on the revolving loan will be accrued and payable only upon certain additional funding of the joint venture by non-affiliated parties. Until repayment, the outstanding revolving loan and interest balance is convertible, at the Company’s option, into Series B Preferred Stock at the Series B-1 conversion price. Losses incurred by the joint venture in excess of the capital accounts of the joint venture will be allocated to the Company to the extent of the unpaid loan and accrued interest balance. At March 31, 2018, the revolving loan agreement balance, including accrued interest subsequent to June 30, 2017 of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">60,000</font>, was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,660,000</font>.</font></div> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The joint venture incurred net operating expenses, prior to the elimination of intercompany transactions, of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">427,000</font> in 2018 and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">10,078,000</font> for the period from August 3, 2012 (inception) to March 31, 2018, of which $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">427,000</font>, and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">8,466,000</font>, respectively, have been recorded by the Company. The joint venture operating expenses are included in research and development expenses in the condensed consolidated statements of operations.</font></div> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">Neither the Company nor the noncontrolling interests have an obligation to contribute additional funds to the joint venture or to assume any joint venture liabilities or to provide a guarantee of either joint venture performance or any joint venture liability. Losses allocated to the common stock noncontrolling interests represent an additional potential loss for the Company as the common stock noncontrolling interests are not obligated to contribute assets to the joint venture and, depending on the ultimate outcome of the joint venture, the Company could potentially absorb all losses associated with the joint venture. From formation of the joint venture, August 3, 2012, through March 31, 2018, losses totaling $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">667,000</font> have been allocated to the common stock noncontrolling interests. If the joint venture or Company is unable to obtain additional funding, the ability of the joint venture to continue development of AEM-28 and its analogs would be impaired as would the joint venture’s ability to continue operations. If the joint venture does not continue as a going concern, at March 31, 2018 the Company would incur an additional loss of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">667,000</font> for the joint venture losses allocated to the common stock noncontrolling interests.</font></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="48"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><b><font style="FONT-SIZE: 10pt">Note D.</font></b></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt" align="justify"><b> <font style="FONT-SIZE: 10pt">CONVERTIBLE PROMISSORY NOTES</font></b></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">On December 11, 2015, we entered into a Securities Purchase Agreement with Biotechnology Value Fund affiliated entities Biotechnology Value Fund, L.P., Biotechnology Value Fund II, L.P., Biotechnology Value Trading Fund OS, L.P., Investment 10, LLC, and MSI BVF SPV,), which provided $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,000,000</font> in funding for our operations in the form of Convertible Promissory Notes (“Notes”). The Notes bear interest at <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 5</font>% and were due April 30, 2017, with the due date subsequently extended to July 14, 2017. The Notes were secured by all intangible and tangible assets of the Company and convertible, either at the election of the Lenders or mandatory on certain future funding events, into either the Company’s Common or Preferred Stock. A portion of the funds were advanced to JV to initiate preclinical development activities. As described in Note E below, the Convertible Promissory Notes and accrued interest thereon of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">79,000</font> were paid off on July 14, 2017. Prior to the July 14, 2017 transaction, the Biotechnology Value Fund affiliated entities owned approximately <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 19</font>% of our outstanding common stock.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

42000

4000

11000

83480

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.3pt; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"></td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="48"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><strong><font style="FONT-SIZE: 10pt">Note E</font></strong></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt" align="justify"> <strong><font style="TEXT-TRANSFORM: uppercase; FONT-SIZE: 10pt"> SALE OF COMMON STOCK AND ISSUANCE OFSECURED debT</font></strong></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <strong><font style="FONT-SIZE: 10pt"> </font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">As described in our Current Report on Form 8-K filed with the Securities and Exchange Commission on July 17, 2017, on July 14, 2017, the Company entered into a Securities Purchase, Loan and Security Agreement (the “Agreement”) with BP Peptides, LLC (“Brookstone"). The net proceeds will be used to fund our operations, infuse new capital into our joint venture, LipimetiX Development, Inc. ("JV") (As described in Note B above, in August 2017, the Company used $1,000,000 of the net proceeds to purchase <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 93,458</font> shares of LipimetiX Development, Inc.’s Series B-2 Preferred Stock.), to continue its development activities, and pay off the Convertible Promissory Notes (as described in Note D above) totaling $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,000,000</font>, plus $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">79,000</font> in accrued interest.</font></div> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">Pursuant to the Agreement, Brookstone funded an aggregate of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">3,440,000</font>, with net proceeds of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2,074,000</font>, after paying off the Convertible Promissory Notes and transaction costs, of which $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,012,500</font> was for the purchase of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 13,500,000</font> newly issued shares of our Common Stock, and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2,427,500</font> was in the form of a secured loan, due October 15, 2020. On July 14, 2017 Brookstone also purchased <font style="LETTER-SPACING: -0.15pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 5,041,197</font> shares of the Company’s Common Stock directly from</font> Biotechnology Value Fund affiliated entities, resulting in ownership of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 18,541,197</font> <font style="LETTER-SPACING: -0.15pt">shares of the Company’s Common Stock, representing approximately <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 34.1</font>% of outstanding shares of the Company’s Common Stock at March 31, 2018. Transaction costs of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">287,000</font> have been deferred and will be written off over the life of the secured loan, thirty-nine months from July 14, 2017 to October 20, 2020, on the straight-line basis. As described in Note F below, additional transaction costs of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">12,000</font> were incurred with the Amendment and will be written off over the period of the date of the Amendment, January 30, 2018, to October 15, 2020. At March 31, 2018 transaction costs of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">64,000</font> ($<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">23,000</font> in 2018 and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">41,000</font> in the second half of 2017), have been amortized and included in the Condensed Consolidated Statements of Operations in Interest and Other Expenses. At March 31, 2018 and December 31, 2017, unamortized transaction costs of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">235,000</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">246,000</font>, respectively, have been netted against the outstanding Secured Debt balance on the Condensed Consolidated Balance Sheets. As discussed in Note F below, interest payable on the Secured Debt is now due at loan maturity, October 15, 2020, and, at March 31, 2018 and December 31, 2017, accrued interest of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">104,000</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">68,000</font>, respectively, has been included in the Secured Debt balance on the Condensed Consolidated Balance Sheets. The interest on the secured debt ($<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">36,000</font> in 2018 and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">68,000</font> in the second half of 2017) has been included in the Condensed Consolidated Statements of Operations in Interest and Other Expenses.</font></font></div> <font style="LETTER-SPACING: -0.15pt; FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="LETTER-SPACING: -0.15pt; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>A summary of the Secured Debt activity is as follows (000’s):</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="center"><font style="LETTER-SPACING: -0.15pt; FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN: 0in 0in 0in 0.5in; WIDTH: 70%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="45%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>March 31, 2018</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>December 31, 2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="45%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Secured Debt</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2,427</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2,427</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Transaction costs</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(299)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(287)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>2,128</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>2,140</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Amortization</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>64</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>41</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>2,192</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>2,181</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Accrued interest</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>104</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>68</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>2,296</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>2,249</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="center"><font style="LETTER-SPACING: -0.15pt; FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The secured loan bears interest at <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">6</font>% per annum, with interest payable quarterly (now due at loan maturity see Note F below) and is secured by a security interest in all of our assets. As part of the Agreement, the Company and Brookstone entered into a Registration Rights Agreement granting Brookstone certain demand and piggyback registration rights. <font style="BACKGROUND: transparent">A provision in the Agreement entered into with Brookstone also requires the Company to nominate two candidates for a director position that have been recommended by Brookstone as long as<font style="FONT-SIZE: 10pt"><font style="BACKGROUND: transparent"><font style="FONT-SIZE: 10pt"><font style="BACKGROUND: transparent"><font style="FONT-SIZE: 10pt"><font style="BACKGROUND: transparent"><font style="FONT-SIZE: 10pt"><font style="BACKGROUND: transparent"><font style="FONT-SIZE: 10pt"><font style="BACKGROUND: transparent"><font style="FONT-SIZE: 10pt"><font style="BACKGROUND: transparent"><font style="FONT-SIZE: 10pt"><font style="BACKGROUND: transparent"><font style="FONT-SIZE: 10pt"><font style="BACKGROUND: transparent"><font style="FONT-SIZE: 10pt"><font style="BACKGROUND: transparent"><font style="FONT-SIZE: 10pt"><font style="BACKGROUND: transparent"><font style="FONT-SIZE: 10pt"><font style="BACKGROUND: transparent"><font style="FONT-SIZE: 10pt"><font style="BACKGROUND: transparent"><font style="FONT-SIZE: 10pt"><font style="BACKGROUND: transparent"><font style="FONT-SIZE: 10pt"><font style="BACKGROUND: transparent"><font style="FONT-SIZE: 10pt"><font style="BACKGROUND: transparent"><font style="FONT-SIZE: 10pt"><font style="BACKGROUND: transparent"><font style="FONT-SIZE: 10pt"><font style="BACKGROUND: transparent"><font style="FONT-SIZE: 10pt"><font style="BACKGROUND: transparent"><font style="FONT-SIZE: 10pt"><font style="BACKGROUND: transparent"><font style="FONT-SIZE: 10pt"><font style="BACKGROUND: transparent"><font style="FONT-SIZE: 10pt"><font style="BACKGROUND: transparent"><font style="FONT-SIZE: 10pt"><font style="BACKGROUND: transparent"><font style="FONT-SIZE: 10pt"><font style="BACKGROUND: transparent"><font style="FONT-SIZE: 10pt"><font style="BACKGROUND: transparent"><font style="FONT-SIZE: 10pt"><font style="BACKGROUND: transparent"><font style="FONT-SIZE: 10pt"><font style="BACKGROUND: transparent"><font style="FONT-SIZE: 10pt"><font style="BACKGROUND: transparent"><font style="FONT-SIZE: 10pt"><font style="BACKGROUND: transparent"><font style="FONT-SIZE: 10pt"><font style="BACKGROUND: transparent"><font style="FONT-SIZE: 10pt"><font style="BACKGROUND: transparent"><font style="FONT-SIZE: 10pt"><font style="BACKGROUND: transparent"><font style="FONT-SIZE: 10pt"><font style="BACKGROUND: transparent"><font style="FONT-SIZE: 10pt"><font style="BACKGROUND: transparent">Brookstone beneficially owns over 20% of the Company’s outstanding common stock and to nominate one candidate for a director position that has been recommended by Brookstone as long as Brookstone beneficially owns over 5% but less than 20% of the Company’s outstanding common stock.</font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font><font style="LETTER-SPACING: -0.15pt; FONT-SIZE: 10pt"> </font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"><font style="BACKGROUND: transparent"><font style="FONT-SIZE: 10pt"><font style="BACKGROUND: transparent"><font style="FONT-SIZE: 10pt"><font style="BACKGROUND: transparent"><font style="FONT-SIZE: 10pt"><font style="BACKGROUND: transparent"><font style="FONT-SIZE: 10pt"><font style="BACKGROUND: transparent"><font style="FONT-SIZE: 10pt"><font style="BACKGROUND: transparent"><font style="FONT-SIZE: 10pt"><font style="BACKGROUND: transparent"><font style="FONT-SIZE: 10pt"><font style="BACKGROUND: transparent"><font style="FONT-SIZE: 10pt"><font style="BACKGROUND: transparent"><font style="FONT-SIZE: 10pt"><font style="BACKGROUND: transparent"><font style="FONT-SIZE: 10pt"><font style="BACKGROUND: transparent"><font style="FONT-SIZE: 10pt"><font style="BACKGROUND: transparent"><font style="FONT-SIZE: 10pt"><font style="BACKGROUND: transparent"><font style="FONT-SIZE: 10pt"><font style="BACKGROUND: transparent"><font style="FONT-SIZE: 10pt"><font style="BACKGROUND: transparent"><font style="FONT-SIZE: 10pt"><font style="BACKGROUND: transparent"><font style="FONT-SIZE: 10pt"><font style="BACKGROUND: transparent"><font style="BACKGROUND: transparent"><font style="LETTER-SPACING: -0.15pt; FONT-SIZE: 10pt"> </font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"><font style="BACKGROUND: transparent"><font style="FONT-SIZE: 10pt"><font style="BACKGROUND: transparent"><font style="FONT-SIZE: 10pt"><font style="BACKGROUND: transparent"><font style="FONT-SIZE: 10pt"><font style="BACKGROUND: transparent"><font style="FONT-SIZE: 10pt"><font style="BACKGROUND: transparent"><font style="FONT-SIZE: 10pt"><font style="BACKGROUND: transparent"><font style="FONT-SIZE: 10pt"><font style="BACKGROUND: transparent"><font style="FONT-SIZE: 10pt"><font style="BACKGROUND: transparent"><font style="FONT-SIZE: 10pt"><font style="BACKGROUND: transparent"><font style="FONT-SIZE: 10pt"><font style="BACKGROUND: transparent"><font style="FONT-SIZE: 10pt"><font style="BACKGROUND: transparent"><font style="FONT-SIZE: 10pt"><font style="BACKGROUND: transparent"><font style="FONT-SIZE: 10pt"><font style="BACKGROUND: transparent"><font style="FONT-SIZE: 10pt"><font style="BACKGROUND: transparent"><font style="FONT-SIZE: 10pt"><font style="BACKGROUND: transparent"><font style="FONT-SIZE: 10pt"><font style="BACKGROUND: transparent"><font style="FONT-SIZE: 10pt"><font style="BACKGROUND: transparent"><font style="BACKGROUND: transparent"><font style="LETTER-SPACING: -0.15pt; FONT-SIZE: 10pt"> </font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font></font><font style="LETTER-SPACING: -0.15pt; FONT-SIZE: 10pt"><font style="LETTER-SPACING: -0.15pt; FONT-SIZE: 10pt">On April 18, 2017, the Company and Computershare Trust Company, N.A., as Rights Agent (the “Rights Agent”) entered into Tax Benefit Preservation Plan Agreement (the “Plan”), dated as of April 18, 2017, between the Company and the Rights Agent, as described in the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on April 19, 2017.  The Plan is intended to act as a deterrent to any person (together with all affiliates and associates of such person) acquiring “beneficial ownership” (as defined in the Plan) of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 4.99</font>% or more of the outstanding shares of Common Stock without the approval of the Board (an “Acquiring Person”), in an effort to protect against a possible limitation on the Company’s ability to use its net operating loss carryforwards.  The Board, in accordance with the Plan, granted an Exemption to Brookstone with respect to the share acquisition described above, and Brookstone’s acquisition of 5,041,197 shares of the Company’s Common Stock from</font> <font style="FONT-SIZE: 10pt">Biotechnology Value Fund affiliated entities, <font style="LETTER-SPACING: -0.15pt">making Brookstone an Exempt Person in respect of such transactions.</font></font></font></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

81479

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="LETTER-SPACING: -0.15pt; FONT-SIZE: 10pt">A summary of the Secured Debt activity is as follows (000’s):</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="center"><font style="LETTER-SPACING: -0.15pt; FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN: 0in 0in 0in 0.5in; WIDTH: 70%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="45%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>March 31, 2018</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>December 31, 2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="45%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Secured Debt</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2,427</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2,427</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Transaction costs</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(299)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(287)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>2,128</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>2,140</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Amortization</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>64</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>41</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>2,192</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>2,181</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Accrued interest</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>104</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>68</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>2,296</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>2,249</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

1.07

0.5

14126

10.70

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <table style="clear:both;WIDTH: 100%; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="48"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><b><font style="FONT-SIZE: 10pt">Note G</font></b></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt" align="justify"><b> <font style="FONT-SIZE: 10pt">SUBSEQUENT EVENT - LIPIMETIX DEVELOPMENT, INC. LICENSE AGREEMENT</font></b></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; BACKGROUND: transparent"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">As described in our Current Report on Form 8-K filed with the Securities and Exchange Commission on May 7, 2018, on May 2, 2018, our JV, LipimetiX Development, Inc., entered into a License Agreement (the “Sub-License”) with Anji Pharmaceuticals Inc. (“ANJI") to sublicense, under its Exclusive License Agreement with the UAB Research Foundation, the use of the JV’s AEM-28 and analogs intellectual property in the Territory of the People’s Republic of China, Taiwan and Hong Kong (the “Territory”). The Sub-License calls for an initial payment of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2,000,000</font>, payment of a royalty on future Net Sales in the Territory and cash milestone payments based on future clinical/regulatory events. ANJI will perform all development activities allowed under the Sub-License in the Territory at its sole cost and expense. As described in Note B above, at March 31, 2018, JV net losses exceeded the JV capital accounts and all losses were being allocated to the Company. Revenue from the initial license payment, when recorded, is expected to reduce the amount of JV net losses previously allocated to the Company.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">A copy of the UAB Research Foundation Exclusive License Agreement was attached as Exhibit 10.7 to the Company’s Quarterly Report on Form 10-Q for the period ending June 30, 2012 filed with Securities and Exchange Commission (‘SEC”) on August 10, 2012. A copy of the First Amendment and Consent to Assignment of the Exclusive License Agreement was attached as Exhibit 10.3 to the Company’s Quarterly Report on Form 10-Q for the period ending June 30, 2012 filed with the SEC on August 10, 2012. The Second Amendment to the Exclusive License Agreement was attached as Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the SEC on January 30, 2015.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

0.6431 1012000

33088

10.70

946000

66000

94537

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <table style="clear:both;WIDTH: 100%; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.3pt; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"></td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="48"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><b><font style="FONT-SIZE: 10pt">Note F</font></b></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt" align="justify"><b> <font style="FONT-SIZE: 10pt">RELATED PARTY TRANSACTION - DEFERRAL OF SECURED DEBT INTEREST PAYMENTS AND ISSUANCE OF WARRANTS TO PURCHASE SHARES OF THE ANY’S COMMON STOCK</font></b></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; BACKGROUND: transparent"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; BACKGROUND: transparent"> <font style="FONT-SIZE: 10pt">As described in our Current Report on Form 8-K filed with the Securities and Exchange Commission on February 1, 2018, on January 30, 2018, the Company entered into the First Amendment to Securities Purchase, Loan and Security Agreement (the “Amendment”) with BP Peptides, LLC (“Brookstone"). Brookstone currently owns approximately <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 34.1</font>% of our outstanding common stock. Under the original Agreement (see Note E above), interest on the Secured Debt was payable quarterly. The Amendment defers the payment of interest until the Secured Debt’s maturity, October 15, 2020. In consideration for the deferral, the Company issued a Warrant to Brookstone to purchase up to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 6,321,930</font> shares of the Company’s Common Stock with an exercise price of $.075 per share. The warrant expires October 15, 2025 and provides for quarterly vesting of shares in amounts approximately equal to the amount of quarterly interest payable that would have been payable under the Agreement, converted into shares at $0.75. At March 31, 2018, <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 984,301</font> shares are fully vested and exercisable.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; BACKGROUND: transparent"> <font style="FONT-SIZE: 10pt">The fair value of the Warrants was determined to be $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">43,000</font>. The fair value of the Warrants will be amortized over the deferral period, January 30, 2018 to October 15, 2020, on the straight-line basis, as additional interest expense. Amortization expenses totaled $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">3,000</font> at March 31, 2018 and is included in Interest and other expenses, net, in the Condensed Consolidated Statement of Operations.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.3pt; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"></td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="48"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><b><font style="FONT-SIZE: 10pt">Note C</font></b></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt" align="justify"><b> <font style="TEXT-TRANSFORM: uppercase; FONT-SIZE: 10pt">Australian Refundable Research & Development Credit</font></b></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">In March 2014, LipimetiX Development LLC, (Now LipimetiX Development, Inc. - see Note B above) formed a wholly-owned Australian subsidiary, Lipimetix Australia Pty Ltd, to conduct Phase 1a and Phase1b/2a clinical trials in Australia. Currently Australian tax regulations provide for a refundable research and development tax credit equal to either <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 43.5</font>% or <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 45</font>% (depending on the tax period) of qualified expenditures. Subsequent to the end of its Australian tax years, Lipimetix Australia Pty Ltd submits claims for a refundable research and development tax credit. At March 31, 2018 and December 31, 2017, expected refundable research and development tax credits of AUD$<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">46,000</font> and AUD$<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">42,000</font>, respectively, are included in Other current assets in the Condensed Consolidated Balance Sheets.  The expected refundable research and development tax credits for the three-month periods ended March 31, 2018 and 2017 were AUD$<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">4,000</font> and AUD$<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">11,000</font>, respectively.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

1045000

0.19

2427000

299000

287000

2128000

2140000

64000

41000

104000

68000

5041197

0.341

18541197

287000

Brookstone beneficially owns over 20% of the Company’s outstanding common stock and to nominate one candidate for a director position that has been recommended by Brookstone as long as Brookstone beneficially owns over 5% but less than 20% of the Company’s outstanding common stock.

15000

0.341

6321930

984301

43000

3000

0.075

2000000

64000

23000

41000

12000

104000

68000

36000

68000

235000

246000

2020-10-15

2025-10-15 2192000 2181000

2017-04-30

2020-10-15

1000000

0.6511

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="center"></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.3pt; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="48"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><b><font style="FONT-SIZE: 10pt">Note A.</font></b></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt" align="justify"><b> <font style="FONT-SIZE: 10pt">OVERVIEW OF BUSINESS</font></b></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 2.25pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in"> <b><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Description of the Business</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">Capstone Therapeutics Corp. (the “Company”, “we”, “our” or “us”) is a biotechnology company committed to developing a pipeline of novel peptides and other molecules aimed at helping patients with under-served medical conditions. Previously, we were focused on the development and commercialization of two product platforms: AZX100 and Chrysalin (TP508). In 2012, we terminated the license for Chrysalin (targeting orthopedic indications). In 2014, we terminated the license for AZX100 (targeting dermal scar reduction). Capstone no longer has any rights to or interest in Chrysalin or AZX100.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">On August 3, 2012, we entered into a joint venture, LipimetiX Development, LLC, (now LipimetiX Development, Inc.), (the “JV”), to develop Apo E mimetic peptide molecule AEM-28 and its analogs. The JV has a development plan to pursue regulatory approval of AEM-28, or an analog, as treatment for Homozygous Familial Hypercholesterolemia, other hyperlipidemic indications, and acute coronary syndrome/atherosclerosis regression. The initial AEM-28 development plan extended through Phase 1a and 1b/2a clinical trials and was completed in the fourth quarter of 2014. The clinical trials had a safety primary endpoint and an efficacy endpoint targeting reduction of cholesterol and triglycerides.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">In early 2014, the JV received allowance from regulatory authorities in Australia permitting the JV to proceed with the planned clinical trials. The Phase 1a clinical trial commenced in Australia in April 2014 and the Phase 1b/2a clinical trial commenced in Australia in June 2014. The clinical trials for AEM-28 were randomized, double-blinded, placebo-controlled studies to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of six escalating single doses (Phase 1a in healthy patients with elevated cholesterol) and multiple ascending doses of the three highest doses from Phase 1a (Phase 1b/2a in patients with hypercholesterolemia and healthy volunteers with elevated cholesterol and high Body Mass Index). The Phase 1a clinical trial consisted of 36 patients and the Phase 1b/2a consisted of 15 patients. Both clinical trials were completed in 2014 and the Medical Safety Committee, reviewing all safety-related aspects of the clinical trials, observed a generally acceptable safety profile. As first-in-man studies, the primary endpoint was safety; yet efficacy measurements analyzing pharmacodynamics yielded statistical significance in the pooled dataset favoring AEM-28 versus placebo in multiple lipid biomarker endpoints.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">Concurrent with the clinical development activities of AEM-28, the JV has performed pre-clinical studies that have identified analogs of AEM-28, and new formulations, that have the potential of increased efficacy, higher human dose toleration and an extended composition of matter patent life (application filed with the U.S. Patent and Trademark Office in 2014).</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The JV and the Company are exploring fundraising, partnering or licensing, to obtain additional funding to continue development activities and operations.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The JV and the Company do not have sufficient funding at this time to continue additional material development activities. The JV may conduct future clinical trials in Australia, the USA, and other regulatory jurisdictions if regulatory approvals, additional funding, and other conditions permit.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The Company, funding permitting, intends to continue limiting its internal operations to a virtual operating model while monitoring and participating in the management of JV’s development activities.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <b><font style="FONT-SIZE: 10pt">Description of Current Peptide Drug Candidates.</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <b><font style="FONT-SIZE: 10pt"> </font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <u><font style="FONT-SIZE: 10pt">Apo E Mimetic Peptide Molecule  AEM-28 and its analogs</font></u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">Apolipoprotein E is a 299 amino acid protein that plays an important role in lipoprotein metabolism. Apolipoprotein E (Apo E) is in a class of protein that occurs throughout the body. Apo E is essential for the normal metabolism of cholesterol and triglycerides. After a meal, the postprandial (or post-meal) lipid load is packaged in lipoproteins and secreted into the blood stream. Apo E targets cholesterol and triglyceride rich lipoproteins to specific receptors in the liver, decreasing the levels in the blood. Elevated plasma cholesterol and triglycerides are independent risk factors for atherosclerosis, the buildup of cholesterol rich lesions and plaques in the arteries. AEM-28 is a 28 amino acid mimetic of Apo E and AEM-28 analogs are also 28 amino acid mimetics of Apo E (with an aminohexanoic acid group and a phospholipid). Both contain a domain that anchors into a lipoprotein surface while also providing the Apo E receptor binding domain, which allows clearance through the heparan sulfate proteoglycan (HSPG) receptors (Syndecan-1) in the liver. AEM-28 and its analogs, as Apo E mimetics, have the potential to restore the ability of these atherogenic lipoproteins to be cleared from the plasma, completing the reverse cholesterol transport pathway, and thereby reducing cardiovascular risk. This is an important mechanism of action for AEM-28 and its analogs. Atherosclerosis is the major cause of cardiovascular disease, peripheral artery disease and cerebral artery disease, and can cause heart attack, loss of limbs and stroke. Defective lipid metabolism also plays an important role in the development of adult onset diabetes mellitus (Type 2 diabetes), and diabetics are particularly vulnerable to atherosclerosis, heart and peripheral artery diseases. Our joint venture has an Exclusive License Agreement with the University of Alabama at Birmingham Research Foundation for a broad domain of Apo E mimetic peptides, including AEM-28 and its analogs.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <b><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Company History</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">Prior to November 2003, we developed, manufactured and marketed proprietary, technologically advanced orthopedic products designed to promote the healing of musculoskeletal bone and tissue, with particular emphasis on fracture healing and spine repair. Our product lines, which included bone growth stimulation and fracture fixation devices, are referred to as our “Bone Device Business.” In November 2003, we sold our Bone Device Business.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">In August 2004, we purchased substantially all of the assets and intellectual property of Chrysalis Biotechnology, Inc., including its exclusive worldwide license for Chrysalin, a peptide, for all medical indications. Subsequently, our efforts were focused on research and development of Chrysalin with the goal of commercializing our products in fresh fracture healing. (In March 2012, we returned all rights to the Chrysalin intellectual property and no longer have any interest in, or rights to, Chrysalin.)</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">In February 2006, we purchased certain assets and assumed certain liabilities of AzERx, Inc. Under the terms of the transaction, we acquired an exclusive license for the core intellectual property relating to AZX100, an anti-fibrotic peptide. In 2014, we terminated the License Agreement with AzTE (Licensor) for the core intellectual property relating to AZX100 and returned all interest in and rights to the AZX100 intellectual property to the Licensor.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">On August 3, 2012, we entered into a joint venture (As described in Note B below) to develop Apo E mimetic peptide molecule AEM-28 and its analogs.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">Our development activities represent a single operating segment as they shared the same product development path and utilized the same Company resources. As a result, we determined that it is appropriate to reflect our operations as one reportable segment.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">OrthoLogic Corp. commenced doing business under the trade name of Capstone Therapeutics on October 1, 2008, and we formally changed our name from OrthoLogic Corp. to Capstone Therapeutics Corp. on May 21, 2010.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">In these notes, references to “we”, “our”, “us”, the “Company”, “Capstone Therapeutics”, “Capstone”, and “OrthoLogic” refer to Capstone Therapeutics Corp. References to our joint venture or “JV”, refer to LipimetiX Development, Inc. (formerly LipimetiX Development, LLC).<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <b><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Basis of presentation, Going Concern, and Management’s Plans.</font></b> <font style="FONT-SIZE: 10pt">The accompanying financials statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <font style="FONT-SIZE: 10pt"><font style="FONT-SIZE: 10pt"><font style="FONT-SIZE: 10pt"></font></font></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> Management has determined that the Company will require additional capital above its current cash and working capital balances to further develop AEM-28 and its analogs or to continue operations. Accordingly, the Company has significantly reduced its development activities. The Company’s corporate strategy is to raise funds by possibly engaging in a strategic/merger transaction or conducting a private or public offering of debt or equity securities for capital. In August 2016, the Company’s joint venture raised net funds of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">946,000</font> in a Series B-1 Preferred Stock and Warrant offering. As described in Note E below, the Company, on July 14, 2017, raised $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">3,440,000</font>, with net proceeds of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2,074,000</font>, after paying off the Convertible Promissory Notes described in Note D below, and transaction costs of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">287,000</font>. As discussed in Note B below, in August 2017, the Company used $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,000,000</font> of the net proceeds to purchase <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 93,458</font> shares of LipimetiX Development, Inc.’s Series B-2 Preferred Stock. Additionally, as disclosed in Note G below, on May 2, 2018, LipimetiX Development, Inc. entered into a License Agreement which will result in the receipt of a $2,000,000 nonrefundable payment. The additional funds has alleviated the substantial doubt about the entity’s ability to continue as a going concern; however, additional funds will be required for the joint venture to reach its development goals and for the Company to continue its planned operations.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">In the opinion of management, the unaudited condensed interim financial statements include all adjustments necessary for the fair presentation of our financial position, results of operations, and cash flows, and all adjustments were of a normal recurring nature. The results of operations for the interim periods are not necessarily indicative of the results to be expected for the complete fiscal year. The financial statements include the consolidated results of Capstone Therapeutics Corp. and our approximately <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 60</font>% owned subsidiary, LipimetiX Development, Inc. Intercompany transactions have been eliminated.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted pursuant to Securities and Exchange Commission rules and regulations, although we believe that the disclosures herein are adequate to make the information presented not misleading. These unaudited condensed financial statements should be read in conjunction with the financial statements and the notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2017. Information presented as of December 31, 2017 is derived from audited financial statements.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <b><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Use of estimates.</font></b> <font style="FONT-SIZE: 10pt"> The preparation of financial statements in accordance with accounting principles generally accepted in the United States of America requires that management make a number of assumptions and estimates that affect the reported amounts of assets, liabilities, and expenses in our financial statements and accompanying notes. Management bases its estimates on historical experience and various other assumptions believed to be reasonable. Although these estimates are based on management’s assumptions regarding current events and actions that may impact the Company in the future, actual results may differ from these estimates and assumptions.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">Our significant estimates include income taxes, contingencies, accounting for stock-based compensation, and accounting for the Australian refundable research and development tax credit.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <b><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Legal and Other Contingencies</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The Company is subject to legal proceedings and claims, as well as potential inquires and action by the Securities and Exchange Commission, that arise in the course of business. The Company records a liability when it is probable that a loss has been incurred and the amount is reasonably estimable. There is significant judgment required in both the probability determination and as to whether an exposure can be reasonably estimated. In the opinion of management, there was not at least a reasonable possibility the Company may have incurred a material loss with respect to loss contingencies. However, the outcome of legal proceedings and claims brought against the Company are subject to significant uncertainty.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">Legal costs related to contingencies are expensed as incurred and were not material in either 2018 or 2017.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><strong> Joint Venture Accounting.</strong></font> <font style="FONT-SIZE: 10pt">The Company entered into a joint venture in which it has contributed $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">6,000,000</font>, and the noncontrolling interests have contributed certain patent license rights. As discussed in Note B below, in August 2017, the Company purchased <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 93,458</font> shares of LipimetiX Development, Inc.’s Series B-2 Preferred Stock for $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,000,000</font>. Neither the Company nor the noncontrolling interests have an obligation to contribute additional funds to the joint venture or to assume any joint venture liabilities or to provide a guarantee of either joint venture performance or any joint venture liability. The financial position and results of operations of the joint venture are presented on a consolidated basis with the financial position and results of operations of the Company. Intercompany transactions have been eliminated. Joint venture losses were recorded on the basis of common ownership equity interests until common ownership equity was reduced to $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0</font>. Subsequent joint venture losses were allocated to the Series A preferred ownership. Subsequent to March 31, 2013, all joint venture losses had been allocated to the Company. On August 25, 2016, the JV raised $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,012,000</font> ($<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">946,000</font> net of issuance costs) in a Series B-1 Preferred Stock and Warrant offering and in 2016, $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">946,000</font> in losses were allocated to the Series B-1 Preferred Stock ownership interests. As of March 31, 2018, losses incurred by the JV exceeded the capital accounts of the JV. The Company has a revolving loan agreement with the joint venture and advanced the joint venture funds for operations in an amount of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,600,000</font>, with the net amount due December 31, 2016. As described in Note B below, the due date of the revolving loan has been extended to July 15, 2020, with early payment required upon certain additional funding of the joint venture by non-affiliated parties. Losses incurred by the joint venture in excess of the capital accounts of the joint venture will be allocated to the Company to the extent of net outstanding advances.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <b><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Cash and cash equivalents.</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">Cash and cash equivalents consist of highly liquid investments with an original maturity of three months or less.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <b>Revenue Recognition</b> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU 606”) No. 2014-09 “Revenue from Contracts from Customers”. Pursuant to ASC 606, revenue is recognized by the Company when a customer obtains control of promised goods or services. The amount of revenue that is recorded reflects the consideration that the Company expects to receive in exchange for those goods or services. The Company applies the following five-step model in order to determine this amount: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <i> </i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <i>Upfront License Fees</i>: If a license to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from nonrefundable, upfront license fees based on the relative value prescribed to the license compared to the total value of the arrangement. The revenue is recognized when the license is transferred to the collaborator and the collaborator is able to use and benefit from the license.  For licenses that are not distinct from other obligations identified in the arrangement, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time. If the combined performance obligation is satisfied over time, the Company applies an appropriate method of measuring progress for purposes of recognizing revenue from nonrefundable, upfront license fees.  The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition<font style="FONT-SIZE: 10pt">.</font></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <b>Revenue Recognition</b> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU 606”) No. 2014-09 “Revenue from Contracts from Customers”. Pursuant to ASC 606, revenue is recognized by the Company when a customer obtains control of promised goods or services. The amount of revenue that is recorded reflects the consideration that the Company expects to receive in exchange for those goods or services. The Company applies the following five-step model in order to determine this amount: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <i> </i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <i>Upfront License Fees</i>: If a license to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from nonrefundable, upfront license fees based on the relative value prescribed to the license compared to the total value of the arrangement. The revenue is recognized when the license is transferred to the collaborator and the collaborator is able to use and benefit from the license.  For licenses that are not distinct from other obligations identified in the arrangement, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time. If the combined performance obligation is satisfied over time, the Company applies an appropriate method of measuring progress for purposes of recognizing revenue from nonrefundable, upfront license fees.  The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition<font style="FONT-SIZE: 10pt">.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

EX-101.SCH 6 caps-20180331.xsd XBRL SCHEMA FILE 101 - Document - Document And Entity Information link:presentationLink link:definitionLink link:calculationLink 102 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS link:presentationLink link:definitionLink link:calculationLink 103 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS [Parenthetical] link:presentationLink link:definitionLink link:calculationLink 104 - Statement - CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS link:presentationLink link:definitionLink link:calculationLink 105 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:definitionLink link:calculationLink 106 - Disclosure - OVERVIEW OF BUSINESS link:presentationLink link:definitionLink link:calculationLink 107 - Disclosure - JOINT VENTURE FOR DEVELOPMENT OF APO E MIMETIC PEPTIDE MOLECULE AEM-28 AND ANALOGS link:presentationLink link:definitionLink link:calculationLink 108 - Disclosure - AUSTRALIAN REFUNDABLE RESEARCH & DEVELOPMENT CREDIT link:presentationLink link:definitionLink link:calculationLink 109 - Disclosure - CONVERTIBLE PROMISSORY NOTES link:presentationLink link:definitionLink link:calculationLink 110 - Disclosure - SALE OF COMMON STOCK AND ISSUANCE OFSECURED DEBT link:presentationLink link:definitionLink link:calculationLink 111 - Disclosure - RELATED PARTY TRANSACTION - DEFERRAL OF SECURED DEBT INTEREST PAYMENTS AND ISSUANCE OF WARRANTS TO PURCHASE SHARES OF THE ANY’S COMMON STOCK link:presentationLink link:definitionLink link:calculationLink 112 - Disclosure - SUBSEQUENT EVENT - LIPIMETIX DEVELOPMENT, INC. LICENSE AGREEMENT link:presentationLink link:definitionLink link:calculationLink 113 - Disclosure - OVERVIEW OF BUSINESS (Policies) link:presentationLink link:definitionLink link:calculationLink 114 - Disclosure - JOINT VENTURE FOR DEVELOPMENT OF APO E MIMETIC PEPTIDE MOLECULE AEM-28 AND ANALOGS (Tables) link:presentationLink link:definitionLink link:calculationLink 115 - Disclosure - SALE OF COMMON STOCK AND ISSUANCE OFSECURED DEBT (Tables) link:presentationLink link:definitionLink link:calculationLink 116 - Disclosure - OVERVIEW OF BUSINESS (Details Textual) link:presentationLink link:definitionLink link:calculationLink 117 - Disclosure - JOINT VENTURE FOR DEVELOPMENT OF APO E MIMETIC PEPTIDE MOLECULE AEM-28 AND ANALOGS (Details) link:presentationLink link:definitionLink link:calculationLink 118 - Disclosure - JOINT VENTURE FOR DEVELOPMENT OF APO E MIMETIC PEPTIDE MOLECULE AEM-28 AND ANALOGS (Details Textual) link:presentationLink link:definitionLink link:calculationLink 119 - Disclosure - AUSTRALIAN REFUNDABLE RESEARCH & DEVELOPMENT CREDIT (Details Textual) link:presentationLink link:definitionLink link:calculationLink 120 - Disclosure - CONVERTIBLE PROMISSORY NOTES (Details Textual) link:presentationLink link:definitionLink link:calculationLink 121 - Disclosure - SALE OF COMMON STOCK AND ISSUANCE OFSECURED DEBT (Details) link:presentationLink link:definitionLink link:calculationLink 122 - Disclosure - SALE OF COMMON STOCK AND ISSUANCE OFSECURED DEBT (Details Textual) link:presentationLink link:definitionLink link:calculationLink 123 - Disclosure - RELATED PARTY TRANSACTION - DEFERRAL OF SECURED DEBT INTEREST PAYMENTS AND ISSUANCE OF WARRANTS TO PURCHASE SHARES OF THE ANY’S COMMON STOCK (Details Textual) link:presentationLink link:definitionLink link:calculationLink 124 - Disclosure - SUBSEQUENT EVENT - LIPIMETIX DEVELOPMENT, INC. LICENSE AGREEMENT (Details Textual) link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 7 caps-20180331_cal.xml XBRL CALCULATION FILE EX-101.DEF 8 caps-20180331_def.xml XBRL DEFINITION FILE EX-101.LAB 9 caps-20180331_lab.xml XBRL LABEL FILE Document And Entity Information [Abstract] Document Information [Table] Legal Entity [Axis] Document Type Amendment Flag Document Period End Date Document Fiscal Year Focus Document Fiscal Period Focus Entity Registrant Name Entity Central Index Key Current Fiscal Year End Date Entity Filer Category Trading Symbol Entity Common Stock, Shares Outstanding Research and Development Expense [Abstract] Refundable Research And Development Credit [Text Block] The entire disclosure for Refundable Research & Development Credit during the period. Accounting Policies [Abstract] Description Of Business [Policy Text Block] Description Of Business [Policy Text Block] Disclosure of accounting policy for description of business. Company History [Policy Text Block] Company History [Policy Text Block] Disclosure of accounting policy for company history. Basis Of Presentation and Management Plan [Policy Text Block] Basis Of Presentation and Management Plan [Policy Text Block] Disclosure of accounting policy for basis of presentation and management plan. Use of Estimates, Policy [Policy Text Block] Use of Estimates, Policy [Policy Text Block] Commitments and Contingencies, Policy [Policy Text Block] Commitments and Contingencies, Policy [Policy Text Block] Interest in Unincorporated Joint Ventures or Partnerships, Policy [Policy Text Block] Interest in Unincorporated Joint Ventures or Partnerships, Policy [Policy Text Block] Cash and Cash Equivalents, Policy [Policy Text Block] Cash and Cash Equivalents, Policy [Policy Text Block] Business Combinations [Abstract] Schedule Of Joint Venture Payments [Table Text Block] Schedule Of Joint Venture Payments [Table Text Block] Tabular disclosure of payments in formation of joint venture. Accounting Policies [Table] Range [Axis] Range [Domain] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets, Major Class Name [Domain] Equity Components [Axis] Equity Component [Domain] Common Stock [Member] Entity [Domain] Lipimetix [Member] Credit Facility [Axis] Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures Joint Venture Losses Recognition Criteria Common Ownership Equity Joint Venture Losses Recognition Criteria, Common Ownership Equity Represents the common ownership equity value, upon which the company records joint venture losses. Equity Method Investment, Ownership Percentage Line of Credit Facility, Maximum Borrowing Capacity Schedule of Related Party Transactions, by Related Party [Table] Related Party Transaction [Line Items] Noncash or Part Noncash Acquisition, Intangible Assets Acquired Patent license rights Patent rights acquired Noncash or Part Noncash Acquisition, Other Liabilities Assumed Noncontrolling interests Noncash or Part Noncash Acquisition, Net Nonmonetary Assets Acquired (Liabilities Assumed) Cash paid at formation Cash paid at formation Voting Common Ownership Units [Member] Non Voting Preferred Ownership Units [Member] Agreement [Axis] Agreement [Domain] Exclusive License Agreement [Member] Maximum [Member] Minimum [Member] Subsequent Event Type [Axis] Subsequent Event Type [Domain] Preferred Stock [Member] Joint Venture Investments In Voting Common Ownership Units Joint Venture Investments In Voting Common Ownership Units (in shares) Share represents joint venture investments in voting common ownership units. Joint Venture Investments In Non Voting Preferred Ownership Units Joint Venture Investments In Non Voting Preferred Ownership Units Share represents joint venture investments in non voting preferred ownership. Joint Venture Investments Common Ownership Units Coventure Joint Venture Investments Common Ownership Units, Co-venture (in shares) Share represents joint venture investments common ownership units of co-venture. Ownership Percentage Coventure Ownership Percentage Co-venture Ownership percentage of co- venture. Percentage Of Royalty Payment Percentage Of Royalty Payment Percentage of royalty payment. Development Activities Monthly Fee Development Activities Monthly Fee Value represents development activities of monthly fee. Joint Venture Operating Expenses Inter Company Transactions Joint Venture, Operating Expenses, Inter Company Transactions Represents the operating expenses incurred by joint venture, in relation to inter company transactions. Joint Venture, Operating Expenses Allocated To Company Joint Venture, Operating Expenses Allocated To Company Represents the operating expenses incurred by joint venture allocated to the company. Annual Maintenance Payments Annual Maintenance Payments It represents the value of annual maintenance payments during the period. Milestone Payments Milestone Payments It represents the value of milestone payments during the period. Royalty Expense Royalty Expense Percentage Of Non Royalty Income Percentage Of Non Royalty Income It represents the percentage of non royalty income. Noncontrolling Interest, Ownership Percentage by Parent Schedule Of Research And Development [Table] Class of Stock [Axis] Class of Stock [Domain] Lipimetix Australia Pty Ltd [Member] Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent Research and Development Expense Statement of Financial Position [Abstract] Statement [Table] Statement [Line Items] Assets [Abstract] ASSETS Assets, Current [Abstract] Current assets Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD CASH AND CASH EQUIVALENTS, END OF PERIOD Other Assets, Current Other current assets Assets, Current Total current assets Finite-Lived Intangible Assets, Net Patent license rights, net Assets Total assets Liabilities and Equity [Abstract] LIABILITIES AND EQUITY Liabilities, Current [Abstract] Current liabilities Accounts Payable, Current Accounts payable Accrued Liabilities, Current Other accrued liabilities Liabilities, Current Total current liabilities Long-term Debt, Unclassified [Abstract] Long-term debt Stockholders' Equity Attributable to Parent [Abstract] Capstone Therapeutics Corp. Stockholders' Equity Common Stock, Value, Issued Common Stock $.0005 par value; 150,000,000 shares authorized; 54,385,411 shares outstanding in 2018 and 2017 Additional Paid In Capital, Common Stock Additional paid-in capital Retained Earnings (Accumulated Deficit) Accumulated deficit Stockholders' Equity Attributable To Parent Total Capstone Therapeutics Corp. stockholders' equity (deficit) Stockholders' Equity Attributable To Noncontrolling Interest Noncontrolling interest Stockholders' Equity, Including Portion Attributable To Noncontrolling Interest Total equity Balance Balance Secured Long-term Debt, Noncurrent Secured debt and accrued interest, net of unamortized issuance costs Balance Sheet [Parenthetical] [Abstract] Balance Sheet Parenthetical. Common Stock, Par Or Stated Value Per Share Common stock, par value (in dollars per share) Common Stock, Shares Authorized Common stock, shares authorized Common Stock, Shares, Outstanding Common stock, shares outstanding Income Statement [Abstract] Operating Expenses [Abstract] OPERATING EXPENSES General and Administrative Expense General and administrative Research and Development Expense (Excluding Acquired In Process Cost) Research and development Operating Expenses Total operating expenses Other Nonoperating Income (Expense) Interest and other expenses, net Income (Loss) From Continuing Operations Before Equity Method Investments, Income Taxes, Extraordinary Items, Cumulative Effects Of Changes In Accounting Principles, Noncontrolling Interest Loss from operations before taxes Income Tax Expense (Benefit) Income tax benefit Income tax provision (benefit) Net Income (Loss), Including Portion Attributable To Noncontrolling Interest Net Loss Net loss Net loss Net Income (Loss) Attributable To Noncontrolling Interest Less: Net Loss attributable to the noncontrolling interest Net Income (Loss) Attributable To Parent Net Loss attributable to Capstone Therapeutics Corp. stockholders Earnings Per Share, Basic and Diluted [Abstract] Per Share Information: Earnings Per Share, Basic and Diluted Net loss, basic and diluted, attributable to Capstone Therapeutics Corp. stockholders Weighted Average Number Of Shares Outstanding, Basic and Diluted Basic and diluted shares outstanding Statement Of Cash Flows [Abstract] Net Cash Provided by (Used in) Operating Activities [Abstract] OPERATING ACTIVITIES Adjustments, Noncash Items, To Reconcile Net Income (Loss) To Cash Provided By (Used In) Operating Activities [Abstract] Non cash items: Depreciation, Depletion and Amortization Amortization Other Noncash Expense Non-cash interest expense Share-Based Compensation Non-cash stock based interest expense Increase (Decrease) In Operating Capital [Abstract] Change in other operating items: Increase (Decrease) in Other Current Assets Other current assets Increase (Decrease) In Accounts Payable Accounts payable Increase (Decrease) in Other Accrued Liabilities Other accrued liabilities Net Cash Provided by (Used in) Operating Activities Cash flows used in operating activities Net Cash Provided by (Used in) Investing Activities [Abstract] INVESTING ACTIVITIES Net Cash Provided by (Used in) Investing Activities Cash flows provided by investing activities Net Cash Provided by (Used in) Financing Activities [Abstract] FINANCING ACTIVITIES Cash and Cash Equivalents, Period Increase (Decrease) NET DECREASE IN CASH AND CASH EQUIVALENTS Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Supplemental Disclosure of Non-Cash Investing Activities - LipimetiX/AzERx/CBI Acquisitions: Business Description and Accounting Policies [Text Block] Business Description and Accounting Policies [Text Block] Business Combination Disclosure [Text Block] Business Combination Disclosure [Text Block] Credit Facility [Domain] Revolving Credit Facility [Member] Long-term Line of Credit Noncontrolling Interest [Member] Debt Disclosure [Abstract] Debt Disclosure [Text Block] Series B2 Preferred Stock [Member] Series B-1 Preferred Stock [Member] Proceeds from Issuance of Preferred Stock and Preference Stock LipimetiX Development, Inc. Series B-1 Preferred Stock, net of issuance costs of $66 Proceeds From Issunance Of Preferred Stock Before Adjusted Stock Issuance Costs Proceeds From Issuance Of Preferred Stock Before Adjusted Stock Issuance Costs Represent that cash inflow for issuance of preferred stock before adjusted stock offering costs. Balance Sheet Location [Axis] Tax Credit Carryforward, Amount Tax Credit Carryforward [Axis] Balance Sheet Location [Domain] Other Current Assets [Member] Research And Development Disclosure [Line Items] Tax Credit Carryforward, Name [Domain] Research Tax Credit Carryforward [Member] Conversion of Stock, Shares Converted Conversion of Stock, Shares Issued Joint Venture Method Investment Ownership Percentage Percentage represents joint venture method investment ownership. Type of Arrangement and Non-arrangement Transactions [Axis] Payments of Stock Issuance Costs Stock Issued During Period, Shares, New Issues Class of Warrant or Right, Number of Securities Called by Warrants or Rights Class of Warrant or Right, Exercise Price of Warrants or Rights Other Commitments [Axis] Arrangements and Non-arrangement Transactions [Domain] Management Fees Amount represents the monthly management fees for services rendered during the period. Professional Fees Management Fee Expense Stockholders' Equity Note [Abstract] Proceeds From Related Party Debt, Net Net Proceeds from related party debt after adjustments. Brookstone [Member] Series B-2 Preferred Stocks [Member] Series B-2 Preferred Stock [Member] Proceeds from Related Party Debt Stock Issued During Period, Value, Acquisitions Stock Issued During Period, Shares, Acquisitions Ownership [Axis] Subsequent Events [Abstract] Convertible Notes Payable, Noncurrent Convertible Promissary Notes Payable Interest Payable Accrued interest Stock Repurchased During Period, Value Stock Repurchased During Period, Shares Debt Instrument, Maturity Date Debt Instrument, Interest Rate, Stated Percentage Short-term Debt, Type [Axis] Debt Instrument, Interest Rate, Effective Percentage Repayments of Convertible Debt Short-term Debt, Type [Domain] Convertible Notes Payable [Member] Series B1 And B2 Preferred Stock [Member] Other Commitment, Due in Second Year Other Commitments [Domain] Accrued Professional Fees Conversion of Stock, Amount Converted Conversion of Stock, Amount Issued EX-101.PRE 10 caps-20180331_pre.xml XBRL PRESENTATION FILE XML 11 R1.htm IDEA: XBRL DOCUMENT

Document And Entity Information - shares	3 Months Ended
Document And Entity Information - shares	Mar. 31, 2018	May 01, 2018
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2018
Document Fiscal Year Focus	2018
Document Fiscal Period Focus	Q1
Entity Registrant Name	Capstone Therapeutics Corp.
Entity Central Index Key	0000887151
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Trading Symbol	CAPS
Entity Common Stock, Shares Outstanding		54,385,411

XML 12 R2.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017
Current assets
Cash and cash equivalents	$ 805	$ 1,275
Other current assets	76	98
Total current assets	881	1,373
Patent license rights, net	157	196
Total assets	1,038	1,569
Current liabilities
Accounts payable	203	197
Other accrued liabilities	3	2
Total current liabilities	206	199
Long-term debt
Secured debt and accrued interest, net of unamortized issuance costs	2,296	2,249
Capstone Therapeutics Corp. Stockholders' Equity
Common Stock $.0005 par value; 150,000,000 shares authorized; 54,385,411 shares outstanding in 2018 and 2017	27	27
Additional paid-in capital	190,470	190,468
Accumulated deficit	(191,961)	(191,374)
Total Capstone Therapeutics Corp. stockholders' equity (deficit)	(1,464)	(879)
Noncontrolling interest	0	0
Total equity	(1,464)	(879)
Total liabilities and equity	$ 1,038	$ 1,569

XML 13 R3.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED BALANCE SHEETS [Parenthetical] - $ / shares	Mar. 31, 2018	Dec. 31, 2017
Common stock, par value (in dollars per share)	$ 0.0005	$ 0.0005
Common stock, shares authorized	150,000,000	150,000,000
Common stock, shares outstanding	54,385,411	54,385,411

XML 14 R4.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
OPERATING EXPENSES
General and administrative	$ 229	$ 113
Research and development	301	267
Total operating expenses	530	380
Interest and other expenses, net	60	15
Loss from operations before taxes	590	395
Income tax benefit	(3)	(8)
Net Loss	587	387
Less: Net Loss attributable to the noncontrolling interest	0	0
Net Loss attributable to Capstone Therapeutics Corp. stockholders	$ 587	$ 387
Per Share Information:
Net loss, basic and diluted, attributable to Capstone Therapeutics Corp. stockholders	$ 0.01	$ 0.01
Basic and diluted shares outstanding	54,385	40,885

XML 15 R5.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
OPERATING ACTIVITIES
Net loss	$ (587)	$ (387)
Non cash items:
Amortization	39	44
Non-cash interest expense	59	0
Non-cash stock based interest expense	2	0
Change in other operating items:
Other current assets	10	44
Accounts payable	6	75
Other accrued liabilities	1	12
Cash flows used in operating activities	(470)	(212)
INVESTING ACTIVITIES
Cash flows provided by investing activities	0	0
FINANCING ACTIVITIES
Cash flows provided by financing activities	0	0
NET DECREASE IN CASH AND CASH EQUIVALENTS	(470)	(212)
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD	1,275	698
CASH AND CASH EQUIVALENTS, END OF PERIOD	$ 805	$ 486

XML 16 R6.htm IDEA: XBRL DOCUMENT

OVERVIEW OF BUSINESS

3 Months Ended

Mar. 31, 2018

Accounting Policies [Abstract]

Business Description and Accounting Policies [Text Block]

Note A.

OVERVIEW OF BUSINESS

Description of the Business

The JV and the Company are exploring fundraising, partnering or licensing, to obtain additional funding to continue development activities and operations.

Description of Current Peptide Drug Candidates.

Apo E Mimetic Peptide Molecule – AEM-28 and its analogs

Company History

On August 3, 2012, we entered into a joint venture (As described in Note B below) to develop Apo E mimetic peptide molecule AEM-28 and its analogs.

Management has determined that the Company will require additional capital above its current cash and working capital balances to further develop AEM-28 and its analogs or to continue operations. Accordingly, the Company has significantly reduced its development activities. The Company’s corporate strategy is to raise funds by possibly engaging in a strategic/merger transaction or conducting a private or public offering of debt or equity securities for capital. In August 2016, the Company’s joint venture raised net funds of $946,000 in a Series B-1 Preferred Stock and Warrant offering. As described in Note E below, the Company, on July 14, 2017, raised $3,440,000, with net proceeds of approximately $2,074,000, after paying off the Convertible Promissory Notes described in Note D below, and transaction costs of $287,000. As discussed in Note B below, in August 2017, the Company used $1,000,000 of the net proceeds to purchase 93,458 shares of LipimetiX Development, Inc.’s Series B-2 Preferred Stock. Additionally, as disclosed in Note G below, on May 2, 2018, LipimetiX Development, Inc. entered into a License Agreement which will result in the receipt of a $2,000,000 nonrefundable payment. The additional funds has alleviated the substantial doubt about the entity’s ability to continue as a going concern; however, additional funds will be required for the joint venture to reach its development goals and for the Company to continue its planned operations.

Our significant estimates include income taxes, contingencies, accounting for stock-based compensation, and accounting for the Australian refundable research and development tax credit.

Legal and Other Contingencies

Legal costs related to contingencies are expensed as incurred and were not material in either 2018 or 2017.

Cash and cash equivalents.

Cash and cash equivalents consist of highly liquid investments with an original maturity of three months or less.

Revenue Recognition

XML 17 R7.htm IDEA: XBRL DOCUMENT

JOINT VENTURE FOR DEVELOPMENT OF APO E MIMETIC PEPTIDE MOLECULE AEM-28 AND ANALOGS

3 Months Ended

Mar. 31, 2018

Business Combinations [Abstract]

Business Combination Disclosure [Text Block]

Note B. JOINT VENTURE FOR DEVELOPMENT OF APO E MIMETIC PEPTIDE MOLECULE AEM-28 AND ANALOGS

As disclosed above, on August 11, 2017, the Company purchased 93,458 shares of LipimetiX Development, Inc.’s Series B-2 Preferred Stock for $1,000,000.

The joint venture formation was as follows ($000’s):

Patent license rights	$	1,045
Noncontrolling interests		(667)
Cash paid at formation	$	378

Patent license rights were recorded at their estimated fair value and are being amortized on a straight-line basis over the key patent life of eighty months.

XML 18 R8.htm IDEA: XBRL DOCUMENT

AUSTRALIAN REFUNDABLE RESEARCH & DEVELOPMENT CREDIT

3 Months Ended

Mar. 31, 2018

Research and Development Expense [Abstract]

Refundable Research And Development Credit [Text Block]

Note C

Australian Refundable Research & Development Credit

XML 19 R9.htm IDEA: XBRL DOCUMENT

CONVERTIBLE PROMISSORY NOTES

3 Months Ended

Mar. 31, 2018

Debt Disclosure [Abstract]

Debt Disclosure [Text Block]

Note D.

CONVERTIBLE PROMISSORY NOTES

XML 20 R10.htm IDEA: XBRL DOCUMENT

SALE OF COMMON STOCK AND ISSUANCE OFSECURED DEBT

3 Months Ended

Mar. 31, 2018

Stockholders' Equity Note [Abstract]

Issuance Of Common Stock And Secured Debt Disclosure [Text Block]

Note E

SALE OF COMMON STOCK AND ISSUANCE OFSECURED debT

A summary of the Secured Debt activity is as follows (000’s):

	March 31, 2018		December 31, 2017

Secured Debt	$	2,427	$	2,427
Transaction costs		(299)		(287)
	$	2,128	$	2,140
Amortization		64		41
	$	2,192	$	2,181
Accrued interest		104		68
	$	2,296	$	2,249

The secured loan bears interest at 6% per annum, with interest payable quarterly (now due at loan maturity see Note F below) and is secured by a security interest in all of our assets. As part of the Agreement, the Company and Brookstone entered into a Registration Rights Agreement granting Brookstone certain demand and piggyback registration rights. A provision in the Agreement entered into with Brookstone also requires the Company to nominate two candidates for a director position that have been recommended by Brookstone as long asBrookstone beneficially owns over 20% of the Company’s outstanding common stock and to nominate one candidate for a director position that has been recommended by Brookstone as long as Brookstone beneficially owns over 5% but less than 20% of the Company’s outstanding common stock.

XML 21 R11.htm IDEA: XBRL DOCUMENT

RELATED PARTY TRANSACTION - DEFERRAL OF SECURED DEBT INTEREST PAYMENTS AND ISSUANCE OF WARRANTS TO PURCHASE SHARES OF THE ANY’S COMMON STOCK

3 Months Ended

Mar. 31, 2018

Note F

RELATED PARTY TRANSACTION - DEFERRAL OF SECURED DEBT INTEREST PAYMENTS AND ISSUANCE OF WARRANTS TO PURCHASE SHARES OF THE ANY’S COMMON STOCK

The fair value of the Warrants was determined to be $43,000. The fair value of the Warrants will be amortized over the deferral period, January 30, 2018 to October 15, 2020, on the straight-line basis, as additional interest expense. Amortization expenses totaled $3,000 at March 31, 2018 and is included in Interest and other expenses, net, in the Condensed Consolidated Statement of Operations.

XML 22 R12.htm IDEA: XBRL DOCUMENT

SUBSEQUENT EVENT - LIPIMETIX DEVELOPMENT, INC. LICENSE AGREEMENT

3 Months Ended

Mar. 31, 2018

Subsequent Events [Abstract]

Subsequent Events [Text Block]

Note G

SUBSEQUENT EVENT - LIPIMETIX DEVELOPMENT, INC. LICENSE AGREEMENT

XML 23 R13.htm IDEA: XBRL DOCUMENT

OVERVIEW OF BUSINESS (Policies)

3 Months Ended

Mar. 31, 2018

Accounting Policies [Abstract]

Description Of Business [Policy Text Block]

Description of the Business

The JV and the Company are exploring fundraising, partnering or licensing, to obtain additional funding to continue development activities and operations.

Description of Current Peptide Drug Candidates.

Apo E Mimetic Peptide Molecule – AEM-28 and its analogs

Company History [Policy Text Block]

Company History

On August 3, 2012, we entered into a joint venture (As described in Note B below) to develop Apo E mimetic peptide molecule AEM-28 and its analogs.

Basis Of Presentation and Management Plan [Policy Text Block]

Management has determined that the Company will require additional capital above its current cash and working capital balances to further develop AEM-28 and its analogs or to continue operations. Accordingly, the Company has significantly reduced its development activities. The Company’s corporate strategy is to raise funds by possibly engaging in a strategic/merger transaction or conducting a private or public offering of debt or equity securities for capital. In August 2016, the Company’s joint venture raised net funds of $946,000 in a Series B-1 Preferred Stock and Warrant offering. As described in Note E below, the Company, on July 14, 2017, raised $3,440,000, with net proceeds of approximately $2,074,000, after paying off the Convertible Promissory Notes described in Note D below, and transaction costs of $287,000. As discussed in Note B below, in August 2017, the Company used $1,000,000 of the net proceeds to purchase 93,458 shares of LipimetiX Development, Inc.’s Series B-2 Preferred Stock. Additionally, as disclosed in Note G below, on May 2, 2018, LipimetiX Development, Inc. entered into a License Agreement which will result in the receipt of a $2,000,000 nonrefundable payment. The additional funds has alleviated the substantial doubt about the entity’s ability to continue as a going concern; however, additional funds will be required for the joint venture to reach its development goals and for the Company to continue its planned operations.

Use of Estimates, Policy [Policy Text Block]

Our significant estimates include income taxes, contingencies, accounting for stock-based compensation, and accounting for the Australian refundable research and development tax credit.

Commitments and Contingencies, Policy [Policy Text Block]

Legal and Other Contingencies

Legal costs related to contingencies are expensed as incurred and were not material in either 2018 or 2017.

Interest in Unincorporated Joint Ventures or Partnerships, Policy [Policy Text Block]

Cash and Cash Equivalents, Policy [Policy Text Block]

Cash and cash equivalents.

Cash and cash equivalents consist of highly liquid investments with an original maturity of three months or less.

Revenue Recognition, Policy [Policy Text Block]

Revenue Recognition

XML 24 R14.htm IDEA: XBRL DOCUMENT

JOINT VENTURE FOR DEVELOPMENT OF APO E MIMETIC PEPTIDE MOLECULE AEM-28 AND ANALOGS (Tables)

3 Months Ended

Mar. 31, 2018

Business Combinations [Abstract]

Schedule Of Joint Venture Payments [Table Text Block]

The joint venture formation was as follows ($000’s):

Patent license rights	$	1,045
Noncontrolling interests		(667)
Cash paid at formation	$	378

XML 25 R15.htm IDEA: XBRL DOCUMENT

SALE OF COMMON STOCK AND ISSUANCE OFSECURED DEBT (Tables)

3 Months Ended

Mar. 31, 2018

Stockholders' Equity Note [Abstract]

Schedule of Debt [Table Text Block]

A summary of the Secured Debt activity is as follows (000’s):

	March 31, 2018		December 31, 2017

Secured Debt	$	2,427	$	2,427
Transaction costs		(299)		(287)
	$	2,128	$	2,140
Amortization		64		41
	$	2,192	$	2,181
Accrued interest		104		68
	$	2,296	$	2,249

XML 26 R16.htm IDEA: XBRL DOCUMENT

OVERVIEW OF BUSINESS (Details Textual) - USD ($)				1 Months Ended
OVERVIEW OF BUSINESS (Details Textual) - USD ($)	Aug. 11, 2017	Jul. 14, 2017	Aug. 03, 2012	Aug. 31, 2017	Aug. 25, 2016	Mar. 31, 2018	Jan. 30, 2018	Aug. 31, 2016
Accounting Policies [Line Items]
Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures		$ 1,000,000	$ 6,000,000			$ 6,000,000
Series B-1 Preferred Stock [Member]
Accounting Policies [Line Items]
Joint Venture Losses Recognition Criteria, Common Ownership Equity					$ 946,000			$ 946,000
Proceeds from Issuance of Preferred Stock and Preference Stock			$ 15,000		946,000
Proceeds From Issuance Of Preferred Stock Before Adjusted Stock Issuance Costs					$ 1,012,000
Stock Issued During Period, Value, Acquisitions	$ 1,000,000
Stock Issued During Period, Shares, Acquisitions	93,458
Series B-2 Preferred Stock [Member]
Accounting Policies [Line Items]
Stock Issued During Period, Value, Acquisitions	$ 1,000,000
Stock Issued During Period, Shares, Acquisitions	93,458			93,458
Payments of Stock Issuance Costs		287,000
Revolving Credit Facility [Member]
Accounting Policies [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity						$ 1,600,000
Lipimetix [Member] \| Ownership As Converted [Member]
Accounting Policies [Line Items]
Equity Method Investment, Ownership Percentage			69.75%			60.00%
Brookstone [Member]
Accounting Policies [Line Items]
Equity Method Investment, Ownership Percentage							34.10%
Proceeds From Related Party Debt, Net		2,074,000
Proceeds from Related Party Debt		$ 3,440,000
Common Stock [Member]
Accounting Policies [Line Items]
Joint Venture Losses Recognition Criteria, Common Ownership Equity						$ 0

XML 27 R17.htm IDEA: XBRL DOCUMENT

JOINT VENTURE FOR DEVELOPMENT OF APO E MIMETIC PEPTIDE MOLECULE AEM-28 AND ANALOGS (Details) - Lipimetix [Member] - USD ($)		3 Months Ended
	Aug. 03, 2012	Mar. 31, 2018
Related Party Transaction [Line Items]
Patent license rights		$ 1,045,000
Noncontrolling interests		(667,000)
Cash paid at formation	$ 378,000	$ 378,000

XML 28 R18.htm IDEA: XBRL DOCUMENT

JOINT VENTURE FOR DEVELOPMENT OF APO E MIMETIC PEPTIDE MOLECULE AEM-28 AND ANALOGS (Details Textual) - USD ($)				1 Months Ended					3 Months Ended		12 Months Ended	68 Months Ended
	Aug. 11, 2017	Aug. 11, 2017	Aug. 03, 2012	Oct. 27, 2017	Aug. 31, 2017	Aug. 25, 2016	Jun. 01, 2016	Mar. 31, 2016	Mar. 31, 2018	Sep. 30, 2017	Dec. 31, 2016	Mar. 31, 2018	Dec. 31, 2017	Jul. 14, 2017	Mar. 31, 2017	Aug. 31, 2016
Related Party Transaction [Line Items]
Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures			$ 6,000,000						$ 6,000,000			$ 6,000,000		$ 1,000,000
Joint Venture Investments In Voting Common Ownership Units (in shares)			600,000
Joint Venture Investments In Non Voting Preferred Ownership Units			5,000,000
Development Activities Monthly Fee			$ 63,000
Joint Venture, Operating Expenses, Inter Company Transactions									427,000			10,078,000
Joint Venture, Operating Expenses Allocated To Company									427,000			8,466,000
Percentage Of Non Royalty Income		5.00%
Conversion of Stock, Shares Converted	3,500,000							1,500,000
Conversion of Stock, Shares Issued								120,000
Joint Venture Method Investment Ownership Percentage			60.00%
Class of Warrant or Right, Number of Securities Called by Warrants or Rights						33,088
Class of Warrant or Right, Exercise Price of Warrants or Rights						$ 10.70
Management Fees							$ 80,000
Professional Fees							$ 10,000
Accrued Professional Fees					$ 20,000
Conversion of Stock, Amount Converted	$ 3,500,000
Conversion of Stock, Amount Issued	1,000,000
Interest Payable									104,000			104,000	$ 68,000
Other Assets, Current									$ 76,000			76,000	$ 98,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant			83,480
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage									50.00%
MrHolliman [Member]
Related Party Transaction [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross				14,126
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price				$ 10.70
Ownership As Converted [Member]
Related Party Transaction [Line Items]
Joint Venture Method Investment Ownership Percentage									65.11%
OwnershipAsConvertedIncludingOptionsAndWarrants [Member]
Related Party Transaction [Line Items]
Joint Venture Method Investment Ownership Percentage				64.31%
Series B2 Preferred Stock [Member]
Related Party Transaction [Line Items]
Joint Venture Losses Recognition Criteria, Common Ownership Equity						$ 946,000										$ 946,000
Proceeds From Issuance Of Preferred Stock Before Adjusted Stock Issuance Costs						1,012,000
Proceeds from Issuance of Preferred Stock and Preference Stock			$ 15,000			946,000
Conversion of Stock, Amount Issued	$ 1,000,000
Stock Issued During Period, Shares, Acquisitions	93,458
Stock Issued During Period, Value, Acquisitions	$ 1,000,000
Series B1 And B2 Preferred Stock [Member]
Related Party Transaction [Line Items]
Joint Venture Method Investment Ownership Percentage			62.20%
Series B1 Preferred Stock [Member]
Related Party Transaction [Line Items]
Joint Venture Losses Recognition Criteria, Common Ownership Equity						946,000
Proceeds From Issuance Of Preferred Stock Before Adjusted Stock Issuance Costs						1,012,000
Proceeds from Issuance of Preferred Stock and Preference Stock						946,000					$ 946,000
Payments of Stock Issuance Costs						$ 66,000
Stock Issued During Period, Shares, New Issues						94,537
Management Fees					$ 300,000						300,000
Professional Fees											60,000
Management Fee Expense										$ 150,000	$ 250,000
Other Commitment, Due in Second Year									$ 150,000			150,000
Accrued Professional Fees									160,000			160,000
Other Assets, Current															$ 50,000
Revolving Credit Facility [Member]
Related Party Transaction [Line Items]
Long-term Line of Credit									1,660,000			1,660,000
Interest Payable									60,000			60,000
Common Stock [Member]
Related Party Transaction [Line Items]
Joint Venture Losses Recognition Criteria, Common Ownership Equity									$ 0			$ 0
Preferred Stock [Member]
Related Party Transaction [Line Items]
Noncontrolling Interest, Ownership Percentage by Parent									100.00%			100.00%
Noncontrolling Interest [Member]
Related Party Transaction [Line Items]
Noncash or Part Noncash Acquisition, Other Liabilities Assumed												$ 667,000,000
Maximum [Member]
Related Party Transaction [Line Items]
Joint Venture Method Investment Ownership Percentage								64.00%
Minimum [Member]
Related Party Transaction [Line Items]
Joint Venture Method Investment Ownership Percentage								60.00%
Exclusive License Agreement [Member]
Related Party Transaction [Line Items]
Percentage Of Royalty Payment		3.00%
Annual Maintenance Payments		$ 25,000
Exclusive License Agreement [Member] \| Maximum [Member]
Related Party Transaction [Line Items]
Milestone Payments		500,000
Royalty Expense		1,000,000
Exclusive License Agreement [Member] \| Minimum [Member]
Related Party Transaction [Line Items]
Milestone Payments		50,000
Royalty Expense		$ 500,000
Lipimetix [Member]
Related Party Transaction [Line Items]
Joint Venture Investments Common Ownership Units, Co-venture (in shares)			400,000
Ownership Percentage Co-venture			40.00%
Noncash or Part Noncash Acquisition, Other Liabilities Assumed									$ 667,000
Noncash or Part Noncash Acquisition, Net Nonmonetary Assets Acquired (Liabilities Assumed)			$ 378,000						$ 378,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross									81,479
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price									$ 1.07
Lipimetix [Member] \| Ownership As Converted [Member]
Related Party Transaction [Line Items]
Equity Method Investment, Ownership Percentage			69.75%						60.00%			60.00%
Voting Common Ownership Units [Member]
Related Party Transaction [Line Items]
Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures			$ 1,000,000
Non Voting Preferred Ownership Units [Member]
Related Party Transaction [Line Items]
Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures			$ 5,000,000

XML 29 R19.htm IDEA: XBRL DOCUMENT

AUSTRALIAN REFUNDABLE RESEARCH & DEVELOPMENT CREDIT (Details Textual) - AUD ($)	1 Months Ended	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2018	Mar. 31, 2017	Dec. 31, 2017
Other Current Assets [Member] \| Research Tax Credit Carryforward [Member]
Research And Development Disclosure [Line Items]
Tax Credit Carryforward, Amount		$ 46,000		$ 42,000
Lipimetix Australia Pty Ltd [Member]
Research And Development Disclosure [Line Items]
Research and Development Expense		$ 4,000	$ 11,000
Lipimetix Australia Pty Ltd [Member] \| Maximum [Member]
Research And Development Disclosure [Line Items]
Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent	45.00%
Lipimetix Australia Pty Ltd [Member] \| Minimum [Member]
Research And Development Disclosure [Line Items]
Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent	43.50%

XML 30 R20.htm IDEA: XBRL DOCUMENT

CONVERTIBLE PROMISSORY NOTES (Details Textual) - USD ($)	Jul. 14, 2017	Dec. 11, 2015
Repayments of Convertible Debt	$ 79,000
Debt Conversion Converted Instrument Shares Issued percentage	19.00%
Convertible Notes Payable [Member]
Convertible Notes Payable, Noncurrent	$ 1,000,000	$ 1,000,000
Debt Instrument, Interest Rate, Effective Percentage		5.00%
Debt Instrument, Maturity Date		Apr. 30, 2017

XML 31 R21.htm IDEA: XBRL DOCUMENT

SALE OF COMMON STOCK AND ISSUANCE OFSECURED DEBT (Details) - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017
Secured Debt	$ 2,427	$ 2,427
Transaction costs	(299)	(287)
Long-term Debt, Gross	2,128	2,140
Amortization	64	41
Secured Long Term Debt, Gross	2,192	2,181
Accrued interest	104	68
Secured Long-term Debt, Noncurrent	$ 2,296	$ 2,249

XML 32 R22.htm IDEA: XBRL DOCUMENT

SALE OF COMMON STOCK AND ISSUANCE OFSECURED DEBT (Details Textual) - USD ($)					1 Months Ended		3 Months Ended	6 Months Ended
	Aug. 11, 2017	Jul. 14, 2017	Jul. 14, 2017	Dec. 11, 2015	Mar. 31, 2018	Jan. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Apr. 18, 2017
Interest Payable					$ 104,000		$ 104,000	$ 68,000
Secured Long-term Debt, Noncurrent					2,296,000		2,296,000	2,249,000
Repayments of Convertible Debt			$ 79,000
Convertible Notes Payable [Member]
Convertible Notes Payable, Noncurrent		$ 1,000,000	1,000,000	$ 1,000,000
Debt Instrument, Maturity Date				Apr. 30, 2017
Interest And Other Expenses [Member]
Interest Expense, Debt					36,000			68,000
Secured Debt [Member]
Interest Payable					104,000		104,000	68,000
Brookstone [Member]
Proceeds from Related Party Debt		3,440,000
Proceeds From Related Party Debt, Net		2,074,000
Stock Repurchased During Period, Value		$ 1,012,500
Stock Repurchased During Period, Shares		13,500,000
Secured Long-term Debt, Noncurrent		$ 2,427,500	$ 2,427,500
Debt Instrument, Interest Rate, Stated Percentage		6.00%	6.00%
Debt Issuance Costs, Net					287,000		287,000
Amortization of Debt Issuance Costs					23,000		64,000	41,000
Unamortized Debt Issuance Expense					$ 235,000		$ 235,000	$ 246,000
Equity Method Investment, Description of Principal Activities			Brookstone beneficially owns over 20% of the Company’s outstanding common stock and to nominate one candidate for a director position that has been recommended by Brookstone as long as Brookstone beneficially owns over 5% but less than 20% of the Company’s outstanding common stock.
Stock Issued During Period, Shares, New Issues			5,041,197				18,541,197
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners					34.10%		34.10%
Payment of Financing and Stock Issuance Costs							$ 12,000
Brookstone [Member] \| Secured Debt [Member]
Debt Instrument, Maturity Date						Oct. 15, 2020	Oct. 15, 2020
Brookstone [Member] \| Minimum [Member]
Beneficial Ownership Percentage									4.99%
Series B2 Preferred Stock [Member]
Stock Issued During Period, Shares, Acquisitions	93,458
Stock Issued During Period, Value, Acquisitions	$ 1,000,000

XML 33 R23.htm IDEA: XBRL DOCUMENT

RELATED PARTY TRANSACTION - DEFERRAL OF SECURED DEBT INTEREST PAYMENTS AND ISSUANCE OF WARRANTS TO PURCHASE SHARES OF THE ANY’S COMMON STOCK (Details Textual) - USD ($)	1 Months Ended	3 Months Ended
	Jan. 30, 2018	Mar. 31, 2018	Aug. 25, 2016
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			33,088
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 10.70
Warrants Not Settleable in Cash, Fair Value Disclosure		$ 43,000
Interest And Other Expenses [Member]
Amortization		$ 3,000
Brookstone [Member]
Equity Method Investment, Ownership Percentage	34.10%
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	6,321,930
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.075
Class Of Warrant Or Right Expiration Date	Oct. 15, 2025
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares	984,301
Brookstone [Member] \| Secured Debt [Member]
Debt Instrument, Maturity Date	Oct. 15, 2020	Oct. 15, 2020

XML 34 R24.htm IDEA: XBRL DOCUMENT

SUBSEQUENT EVENT - LIPIMETIX DEVELOPMENT, INC. LICENSE AGREEMENT (Details Textual)	May 02, 2018 USD ($)
Lipimetix [Member] \| Subsequent Event [Member]
Royalty Revenue	$ 2,000,000

EXCEL 35 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 36 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 37 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 39 FilingSummary.xml IDEA: XBRL DOCUMENT 3.8.0.1 html 80 143 1 false 25 0 false 5 false false R1.htm 101 - Document - Document And Entity Information Sheet http://www.capstonethx.com/role/DocumentAndEntityInformation Document And Entity Information Cover 1 false false R2.htm 102 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS Sheet http://www.capstonethx.com/role/CondensedConsolidatedBalanceSheets CONDENSED CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 103 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS [Parenthetical] Sheet http://www.capstonethx.com/role/CondensedConsolidatedBalanceSheetsParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS [Parenthetical] Statements 3 false false R4.htm 104 - Statement - CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS Sheet http://www.capstonethx.com/role/CondensedConsolidatedStatementOfOperations CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS Statements 4 false false R5.htm 105 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://www.capstonethx.com/role/CondensedConsolidatedStatementsOfCashFlows CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 5 false false R6.htm 106 - Disclosure - OVERVIEW OF BUSINESS Sheet http://www.capstonethx.com/role/OverviewOfBusiness OVERVIEW OF BUSINESS Notes 6 false false R7.htm 107 - Disclosure - JOINT VENTURE FOR DEVELOPMENT OF APO E MIMETIC PEPTIDE MOLECULE AEM-28 AND ANALOGS Sheet http://www.capstonethx.com/role/JointVentureForDevelopmentOfApoEMimeticPeptideMoleculeAem28AndAnalogs JOINT VENTURE FOR DEVELOPMENT OF APO E MIMETIC PEPTIDE MOLECULE AEM-28 AND ANALOGS Notes 7 false false R8.htm 108 - Disclosure - AUSTRALIAN REFUNDABLE RESEARCH & DEVELOPMENT CREDIT Sheet http://www.capstonethx.com/role/AustralianRefundableResearchDevelopmentCredit AUSTRALIAN REFUNDABLE RESEARCH & DEVELOPMENT CREDIT Notes 8 false false R9.htm 109 - Disclosure - CONVERTIBLE PROMISSORY NOTES Notes http://www.capstonethx.com/role/ConvertiblePromissoryNotes CONVERTIBLE PROMISSORY NOTES Notes 9 false false R10.htm 110 - Disclosure - SALE OF COMMON STOCK AND ISSUANCE OFSECURED DEBT Sheet http://www.capstonethx.com/role/SaleOfCommonStockAndIssuanceOfsecuredDebt SALE OF COMMON STOCK AND ISSUANCE OFSECURED DEBT Notes 10 false false R11.htm 111 - Disclosure - RELATED PARTY TRANSACTION - DEFERRAL OF SECURED DEBT INTEREST PAYMENTS AND ISSUANCE OF WARRANTS TO PURCHASE SHARES OF THE ANY???S COMMON STOCK Sheet http://www.capstonethx.com/role/RelatedPartyTransactionDeferralOfSecuredDebtInterestPaymentsAndIssuanceOfWarrantsToPurchaseSharesOfAnysCommonStock RELATED PARTY TRANSACTION - DEFERRAL OF SECURED DEBT INTEREST PAYMENTS AND ISSUANCE OF WARRANTS TO PURCHASE SHARES OF THE ANY???S COMMON STOCK Notes 11 false false R12.htm 112 - Disclosure - SUBSEQUENT EVENT - LIPIMETIX DEVELOPMENT, INC. LICENSE AGREEMENT Sheet http://www.capstonethx.com/role/SubsequentEventLipimetixDevelopmentIncLicenseAgreement SUBSEQUENT EVENT - LIPIMETIX DEVELOPMENT, INC. LICENSE AGREEMENT Notes 12 false false R13.htm 113 - Disclosure - OVERVIEW OF BUSINESS (Policies) Sheet http://www.capstonethx.com/role/OverviewOfBusinessPolicies OVERVIEW OF BUSINESS (Policies) Policies 13 false false R14.htm 114 - Disclosure - JOINT VENTURE FOR DEVELOPMENT OF APO E MIMETIC PEPTIDE MOLECULE AEM-28 AND ANALOGS (Tables) Sheet http://www.capstonethx.com/role/JointVentureForDevelopmentOfApoEMimeticPeptideMoleculeAem28AndAnalogsTables JOINT VENTURE FOR DEVELOPMENT OF APO E MIMETIC PEPTIDE MOLECULE AEM-28 AND ANALOGS (Tables) Tables http://www.capstonethx.com/role/JointVentureForDevelopmentOfApoEMimeticPeptideMoleculeAem28AndAnalogs 14 false false R15.htm 115 - Disclosure - SALE OF COMMON STOCK AND ISSUANCE OFSECURED DEBT (Tables) Sheet http://www.capstonethx.com/role/SaleOfCommonStockAndIssuanceOfsecuredDebtTables SALE OF COMMON STOCK AND ISSUANCE OFSECURED DEBT (Tables) Tables http://www.capstonethx.com/role/SaleOfCommonStockAndIssuanceOfsecuredDebt 15 false false R16.htm 116 - Disclosure - OVERVIEW OF BUSINESS (Details Textual) Sheet http://www.capstonethx.com/role/OverviewOfBusinessDetailsTextual OVERVIEW OF BUSINESS (Details Textual) Details http://www.capstonethx.com/role/OverviewOfBusinessPolicies 16 false false R17.htm 117 - Disclosure - JOINT VENTURE FOR DEVELOPMENT OF APO E MIMETIC PEPTIDE MOLECULE AEM-28 AND ANALOGS (Details) Sheet http://www.capstonethx.com/role/JointVentureForDevelopmentOfApoEMimeticPeptideMoleculeAem28AndAnalogsDetails JOINT VENTURE FOR DEVELOPMENT OF APO E MIMETIC PEPTIDE MOLECULE AEM-28 AND ANALOGS (Details) Details http://www.capstonethx.com/role/JointVentureForDevelopmentOfApoEMimeticPeptideMoleculeAem28AndAnalogsTables 17 false false R18.htm 118 - Disclosure - JOINT VENTURE FOR DEVELOPMENT OF APO E MIMETIC PEPTIDE MOLECULE AEM-28 AND ANALOGS (Details Textual) Sheet http://www.capstonethx.com/role/JointVentureForDevelopmentOfApoEMimeticPeptideMoleculeAem28AndAnalogsDetailsTextual JOINT VENTURE FOR DEVELOPMENT OF APO E MIMETIC PEPTIDE MOLECULE AEM-28 AND ANALOGS (Details Textual) Details http://www.capstonethx.com/role/JointVentureForDevelopmentOfApoEMimeticPeptideMoleculeAem28AndAnalogsTables 18 false false R19.htm 119 - Disclosure - AUSTRALIAN REFUNDABLE RESEARCH & DEVELOPMENT CREDIT (Details Textual) Sheet http://www.capstonethx.com/role/AustralianRefundableResearchDevelopmentCreditDetailsTextual AUSTRALIAN REFUNDABLE RESEARCH & DEVELOPMENT CREDIT (Details Textual) Details http://www.capstonethx.com/role/AustralianRefundableResearchDevelopmentCredit 19 false false R20.htm 120 - Disclosure - CONVERTIBLE PROMISSORY NOTES (Details Textual) Notes http://www.capstonethx.com/role/ConvertiblePromissoryNotesDetailsTextual CONVERTIBLE PROMISSORY NOTES (Details Textual) Details http://www.capstonethx.com/role/ConvertiblePromissoryNotes 20 false false R21.htm 121 - Disclosure - SALE OF COMMON STOCK AND ISSUANCE OFSECURED DEBT (Details) Sheet http://www.capstonethx.com/role/SaleOfCommonStockAndIssuanceOfsecuredDebtDetails SALE OF COMMON STOCK AND ISSUANCE OFSECURED DEBT (Details) Details http://www.capstonethx.com/role/SaleOfCommonStockAndIssuanceOfsecuredDebtTables 21 false false R22.htm 122 - Disclosure - SALE OF COMMON STOCK AND ISSUANCE OFSECURED DEBT (Details Textual) Sheet http://www.capstonethx.com/role/SaleOfCommonStockAndIssuanceOfsecuredDebtDetailsTextual SALE OF COMMON STOCK AND ISSUANCE OFSECURED DEBT (Details Textual) Details http://www.capstonethx.com/role/SaleOfCommonStockAndIssuanceOfsecuredDebtTables 22 false false R23.htm 123 - Disclosure - RELATED PARTY TRANSACTION - DEFERRAL OF SECURED DEBT INTEREST PAYMENTS AND ISSUANCE OF WARRANTS TO PURCHASE SHARES OF THE ANY???S COMMON STOCK (Details Textual) Sheet http://www.capstonethx.com/role/RelatedPartyTransactionDeferralOfSecuredDebtInterestPaymentsAndIssuanceOfWarrantsToPurchaseSharesOfAnysCommonStockDetailsTextual RELATED PARTY TRANSACTION - DEFERRAL OF SECURED DEBT INTEREST PAYMENTS AND ISSUANCE OF WARRANTS TO PURCHASE SHARES OF THE ANY???S COMMON STOCK (Details Textual) Details http://www.capstonethx.com/role/RelatedPartyTransactionDeferralOfSecuredDebtInterestPaymentsAndIssuanceOfWarrantsToPurchaseSharesOfAnysCommonStock 23 false false R24.htm 124 - Disclosure - SUBSEQUENT EVENT - LIPIMETIX DEVELOPMENT, INC. LICENSE AGREEMENT (Details Textual) Sheet http://www.capstonethx.com/role/SubsequentEventLipimetixDevelopmentIncLicenseAgreementDetailsTextual SUBSEQUENT EVENT - LIPIMETIX DEVELOPMENT, INC. LICENSE AGREEMENT (Details Textual) Details http://www.capstonethx.com/role/SubsequentEventLipimetixDevelopmentIncLicenseAgreement 24 false false All Reports Book All Reports caps-20180331.xml caps-20180331.xsd caps-20180331_cal.xml caps-20180331_def.xml caps-20180331_lab.xml caps-20180331_pre.xml http://xbrl.sec.gov/dei/2014-01-31 http://fasb.org/us-gaap/2017-01-31 true true ZIP 41 0001171843-18-003863-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001171843-18-003863-xbrl.zip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�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end